1
|
Maslii Y, Kolisnyk T, Ruban O, Yevtifieieva O, Gureyeva S, Goy A, Kasparaviciene G, Kalveniene Z, Bernatoniene J. Impact of Compression Force on Mechanical, Textural, Release and Chewing Perception Properties of Compressible Medicated Chewing Gums. Pharmaceutics 2021; 13:pharmaceutics13111808. [PMID: 34834223 PMCID: PMC8621342 DOI: 10.3390/pharmaceutics13111808] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/09/2021] [Revised: 10/13/2021] [Accepted: 10/20/2021] [Indexed: 11/16/2022] Open
Abstract
Medicated chewing gums (MCGs) represent a beneficial platform for realizing drugs intended for dental prophylaxis and treatment. The present study aimed to investigate the impact of compression force on the mechanical, textural, release, and chewing perception characteristics of compressible MCGs with the combination of lysozyme hydrochloride (LH) and ascorbic acid (AsA). Four batches of MCGs were obtained on a laboratory single-punch tablet machine applying different forces, i.e., 5, 7, 10, and 15 kN, and evaluated by their geometrical parameters, mechanical resistance, surface and internal structure characteristics, texture profile, release behavior, and perception attributes during mastication. It was found that increasing compression force slightly affected resistance to crushing and friability of MCGs, but resulted in surface smoothing and formation of a thicker layer with highly compacted particle arrangement. According to the texture analysis, increasing compression force led to harder and more adhesive gums, indicating possible difficulties in chewing and, therefore, impairment of their consumer properties. Lower compression forces were also found to be preferable in terms of better drug release from the obtained chewing gums. The volunteers’ assessment showed that an increase of compression force led to significantly raising the initial hardness and crumbliness as well as to decreasing the rate of the integral gum mass formation during mastication, which may negatively affect perceptive sensations when using MCGs. Based on the results obtained, the optimal compressing force was selected to be 7 kN, which allows obtaining MCGs with good organoleptic, mechanical, textural, and release properties.
Collapse
Affiliation(s)
- Yuliia Maslii
- Department of Industrial Technology of Drugs, National University of Pharmacy, 61002 Kharkiv, Ukraine; (Y.M.); (T.K.); (O.R.)
| | - Tetiana Kolisnyk
- Department of Industrial Technology of Drugs, National University of Pharmacy, 61002 Kharkiv, Ukraine; (Y.M.); (T.K.); (O.R.)
| | - Olena Ruban
- Department of Industrial Technology of Drugs, National University of Pharmacy, 61002 Kharkiv, Ukraine; (Y.M.); (T.K.); (O.R.)
| | - Olga Yevtifieieva
- Department of Pharmaceutical Chemistry, National University of Pharmacy, 61002 Kharkiv, Ukraine;
| | | | - Andriy Goy
- JSC Farmak, 04080 Kyiv, Ukraine; (S.G.); (A.G.)
| | - Giedre Kasparaviciene
- Department of Drug Technology and Social Pharmacy, Lithuanian University of Health Sciences, LT-50161 Kaunas, Lithuania; (G.K.); (Z.K.)
| | - Zenona Kalveniene
- Department of Drug Technology and Social Pharmacy, Lithuanian University of Health Sciences, LT-50161 Kaunas, Lithuania; (G.K.); (Z.K.)
| | - Jurga Bernatoniene
- Department of Drug Technology and Social Pharmacy, Lithuanian University of Health Sciences, LT-50161 Kaunas, Lithuania; (G.K.); (Z.K.)
- Correspondence: ; Tel.: +370-60063349
| |
Collapse
|
2
|
Wang M, Rule S, Zinzani PL, Goy A, Casasnovas O, Smith SD, Damaj G, Doorduijn JK, Lamy T, Morschhauser F, Panizo C, Shah B, Davies A, Eek R, Dupuis J, Jacobsen E, Kater AP, Gouill S, Oberic L, Robak T, Jain P, Calvo R, Tao L, Dlugosz‐Danecka M. ACALABRUTINIB MONOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA: FINAL RESULTS FROM A PHASE 2 STUDY. Hematol Oncol 2021. [DOI: 10.1002/hon.58_2880] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- M. Wang
- MD Anderson Cancer Center, University of Texas Lymphoma ‐ Myeloma, Division of Cancer Medicine Houston Texas USA
| | - S. Rule
- Plymouth University Medical School Hematology Plymouth UK
| | - P. L. Zinzani
- Institute of Hematology “Seràgnoli” University of Bologna Experimental, Diagnostic and Specialty Medicine ‐ DIMES Bologna Italy
| | - A. Goy
- John Theurer Cancer Center, Hackensack University Medical Center Oncology Hackensack New Jersey USA
| | - O. Casasnovas
- CHU Dijon ‐ Hôpital d’Enfants Hematology Dijon France
| | - S. D. Smith
- Fred Hutchinson Cancer Research Center, University of Washington Medical Oncology Seattle Washington USA
| | - G. Damaj
- Institut d’Hématologie de Basse‐Normandie Hematology Caen France
| | - J. K. Doorduijn
- Erasmus MC, HOVON Lunenburg Lymphoma Phase I/II Consortium Hematology Rotterdam Netherlands
| | - T. Lamy
- CHU de Rennes Hematology Rennes France
| | - F. Morschhauser
- CHU Lille, ULR 7365 ‐ GRITA ‐ Groupe de Recherche sur les formes Injectables et les Technologies Associées Hematology Lille France
| | - C. Panizo
- Clínica Universidad de Navarra Hematology Pamplona Spain
| | - B. Shah
- Moffitt Cancer Center Malignant Hematology Tampa Florida USA
| | - A. Davies
- Cancer Research UK Experimental Cancer Medicines Centre, University of Southampton Faculty of Medicine Medical Oncology Southampton UK
| | - R. Eek
- Border Medical Oncology Medical Oncology Albury Australia
| | - J. Dupuis
- Unité Hémopathies Lymphoïdes AP‐HP Hôpital Henri Mondor, Hematology Créteil France
| | - E. Jacobsen
- Dana Farber Cancer Institute Harvard Medical School, Medical Oncology Boston Massachusetts USA
| | - A. P. Kater
- Amsterdam University Medical Center Amsterdam, on behalf of Hovon, Hematology, Lymphoma and Myeloma Research Amsterdam Netherlands
| | - S. Gouill
- CHU de Nantes—Hotel Dieu Hematology Nantes France
| | - L. Oberic
- Institut Universitaire du Cancer—Oncopole Toulouse (IUCT‐O) Hematology Toulouse France
| | - T. Robak
- Copernicus Memorial Hospital, Medical University of Lodz Hematology Lodz Poland
| | - P. Jain
- MD Anderson Cancer Center, University of Texas Leukemia Houston Texas USA
| | - R. Calvo
- AstraZeneca, Clinical Development Hematology R&D Oncology Gaithersburg Maryland USA
| | - L. Tao
- AstraZeneca Biostatistics South San Francisco California USA
| | - M. Dlugosz‐Danecka
- Maria Sklodowska‐Curie National Research Institute of Oncology Hematology Krakow Poland
| |
Collapse
|
3
|
Maslii Y, Ruban L, Yevtifieieva O, Hrudko V, Gureyeva S, Goy A, Kolisnyk T. Development and uniformity evaluation of low-dose medicated chewing gums prepared by compression method. Ceska Slov Farm 2020; 69:33-42. [PMID: 32460508] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/11/2023]
Abstract
The aim of this work was to develop medicated chewing gums (MCGs) containing 10 mg of lysozyme hydrochloride (LH) and 20 mg of ascorbic acid (AsA) obtained by the compression method with Health in Gum® (HiG®) PWD 01 as a compressible gum base. Because of a low content of active ingredients, it was essential to choose the way of adding them to the tableting mass and evaluate their distribution homogeneity in the dosage units. The blends for compression were prepared by two methods: the first one was simple mixing of all components; the second one included the step of wet granulation of a three-component mixture - LH, sucralose and a taste additive. Flow properties of LH, AsA, HiG®, LH granules and blends for compression were studied. MCGs were evaluated according to Ph.Eur. 9.0 Chapters 2.9.5, 2.9.6 and 2.9.40. AsA and HiG® were characterized as free flowing, while LH had insufficient flow properties. Compared with a simple mixed blend, the granulation step allowed significantly improving flow properties of the final blend for compression. Unlike MCGs compressed from the simple mixed blend, MCGs prepared through the granulation step met Ph.Eur. 9.0 Chapter 2.9.40 requirements. The propriety of MCG preparation method involving the step of wet granulation also has been confirmed by mass and drug content uniformity tests.
Collapse
|
4
|
Jurczak W, Zinzani PL, Gaidano G, Goy A, Provencio M, Nagy Z, Robak T, Maddocks K, Buske C, Ambarkhane S, Winderlich M, Dirnberger-Hertweck M, Korolkiewicz R, Blum KA. Phase IIa study of the CD19 antibody MOR208 in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma. Ann Oncol 2019; 29:1266-1272. [PMID: 29444231 PMCID: PMC5961010 DOI: 10.1093/annonc/mdy056] [Citation(s) in RCA: 92] [Impact Index Per Article: 18.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022] Open
Abstract
Background This two-stage, phase IIa study investigated the antitumor activity and safety of MOR208, an Fc-engineered, humanized, CD19 antibody, in patients with relapsed or refractory (R-R) B-cell non-Hodgkin’s lymphoma (NHL). CD19 is broadly expressed across the B-lymphocyte lineage, including in B-cell malignancies, but not by hematological stem cells. Patients and methods Patients aged ≥18 years, with R-R NHL progressing after ≥1 prior rituximab-containing regimen were enrolled into subtype-specific cohorts: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), other indolent (i)NHL and mantle cell lymphoma (MCL). Treatment was MOR208, 12 mg/kg intravenously, weekly, for 8 weeks. Patients with at least stable disease could continue treatment for an additional 4 weeks. Those with a partial or complete response after 12 weeks could receive extended MOR208 treatment (12 mg/kg, either monthly or every second week) until progression. The primary end point was overall response rate. Results Ninety-two patients were enrolled: DLBCL (n = 35), FL (n = 34), other iNHL (n = 11) and MCL (n = 12). Responses were observed in DLBCL, FL and other iNHL cohorts (26%, 29% and 27%, respectively). They lasted ≥12 months in 5/9 responding patients with DLBCL, 4/9 with FL and 2/3 with other iNHL. Responses in nine patients are ongoing (>26 months in five instances). Patients with rituximab refractory disease showed a similar response rate and progression-free survival time to patients with non-refractory disease. The most common adverse events (any grade) were infusion-related reactions (12%) and neutropenia (12%). One patient experienced a grade 4 infusion-related reaction and eight patients (9%) experienced grade 3/4 neutropenia. No treatment-related deaths were reported. Conclusions MOR208 monotherapy demonstrated promising clinical activity in patients with R-R DLBCL and R-R FL, including in patients with rituximab refractory tumors. These efficacy data and the favorable safety profile support further investigation of MOR208 in phase II/III combination therapy trials in R-R DLBCL. ClinicalTrials.gov number NCT01685008.
Collapse
Affiliation(s)
- W Jurczak
- Department of Hematology, Jagiellonian University, Kraków, Poland.
| | - P L Zinzani
- Institute of Hematology "L. e A. Seràgnoli", University of Bologna, Bologna
| | - G Gaidano
- Division of Hematology, Department of Translational Medicine, University of Eastern Piedmont, Novara, Italy
| | - A Goy
- John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, USA
| | - M Provencio
- Department of Medical Oncology, University Hospital Puerta De Hierro, Madrid, Spain
| | - Z Nagy
- First Department of Internal Medicine, Semmelweis University, Budapest, Hungary
| | - T Robak
- Department of Hematology, Medical University of Lodz and Copernicus Memorial Hospital, Lodz, Poland
| | - K Maddocks
- Division of Hematology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, USA
| | - C Buske
- Comprehensive Cancer Center Ulm, Institute of Experimental Cancer Research, University Hospital of Ulm, Ulm
| | | | | | | | | | - K A Blum
- Division of Hematology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, USA
| |
Collapse
|
5
|
Kalakonda N, Cavallo F, Follows G, Goy A, Vermaat J, Casasnovas O, Lavee O, Maerevoet M, Zijlstra J, Bakshi S, Bouabdallah R, Choquet S, Gurion R, Hill B, Jaeger U, Sancho J, Schuster M, Thieblemont C, De la Cruz F, Egyed M, Mishra S, Offner F, Vassilakopoulos T, Warzocha K, Oluyadi A, McCarthy D, Ma X, Corona K, Shah J, Van Den Neste E, Canales M. A PHASE 2B STUDY OF SELINEXOR IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL). Hematol Oncol 2019. [DOI: 10.1002/hon.31_2629] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- N. Kalakonda
- Molecular and Clinical Cancer Medicine; University of Liverpool; Liverpool United Kingdom
| | - F. Cavallo
- Molecular Biotechnology and Health Sciences; Aziena Ospedaliero - Universitaria Città della Salute e della Scienza di Torino; Turin Italy
| | - G. Follows
- Haematology; Cambridge University Hospitals NHS Foundation Trust Addenbrooke's Hospital; Cambridge United Kingdom
| | - A. Goy
- Oncology; Hackensack University Medical Center; Hackensack United States
| | - J. Vermaat
- Hematology; Leiden University Medical Center; Leiden Netherlands
| | | | - O. Lavee
- Hematology; St. Vincent's Hospital Sydney; Darlinghurst Australia
| | - M. Maerevoet
- Hematology; Service Hématologie, Institut Bordet; Bruxelles Belgium
| | - J. Zijlstra
- Hematology; Amsterdam UMC; Amsterdam Netherlands
| | - S. Bakshi
- Medical Oncology; Dr. B. R. A. Institute Rotary Cancer Hospital; New Delhi India
| | - R. Bouabdallah
- Oncology/Hematology; Institut Paoli-Calmettes; Marseille France
| | - S. Choquet
- Hematology; Hospital Pitie Salpetriere; Paris France
| | - R. Gurion
- Hematology; Rabin MC; Petah Tiqwa Israel
| | - B. Hill
- Hematology and Medical Oncology; Cleveland Clinic Main Campus; Cleveland United States
| | - U. Jaeger
- Medicine I; Medical University of Vienna; Vienna Austria
| | - J. Sancho
- Clinical Hematology; Hospital Germans Trias i Pujol; Barcelona Spain
| | - M. Schuster
- Medicine; Stony Brook University; Stony Brook United States
| | | | - F. De la Cruz
- Hematology; Hospital Universitario Virgen del Rocío; Sevilla Spain
| | - M. Egyed
- Hematology; Teaching Hospital Mór Kaposi; Kaposvár Hungary
| | - S. Mishra
- Medical Oncology; Institute of Medical Sciences & SUM Hospital; Bhubaneswar India
| | | | | | - K. Warzocha
- Hematology; Instytut Hematologii i Transfuzjologii; Warszawa Poland
| | - A. Oluyadi
- Clinical Development; Karyopharm Therapeutics Inc.; Newton United States
| | - D. McCarthy
- Clinical Operations; Karyopharm Therapeutics Inc.; Newton United States
| | - X. Ma
- Biostatistics; Karyopharm Therapeutics Inc.; Newton United States
| | - K. Corona
- Medical Affairs; Karyopharm Therapeutics Inc.; Newton United States
| | - J. Shah
- Clinical Development; Karyopharm Therapeutics Inc.; Newton United States
| | - E. Van Den Neste
- Hematology; Cliniques Universitaires Saint-Luc; Brussels Belgium
| | - M. Canales
- Medicine; Hospital Universitario La Paz; Madrid Spain
| |
Collapse
|
6
|
Wang M, Belada D, Cheah C, Chu M, Dreyling M, Flinn I, Fogliatto L, Goy A, Inwards D, Jurczak W, Mayer J, Re F, Robak T, Spurgeon S, Yoon S, Zinzani P, Yin M, Chen T, Kahl B. A PHASE 3 STUDY OF ACALABRUTINIB PLUS BENDAMUSTINE AND RITUXIMAB IN ELDERLY (AGED ≥65 Years) TREATMENT-NAIVE PATIENTS WITH MANTLE CELL LYMPHOMA. Hematol Oncol 2019. [DOI: 10.1002/hon.2632] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- M. Wang
- Department of Lymphoma/Myeloma; The University of Texas MD Anderson Cancer Center; Houston United States
| | - D. Belada
- Charles University Hospital and Faculty of Medicine; Fourth Department of Internal Medicine-Hematology; Hradec Králové Czech Republic
| | - C. Cheah
- Comprehensive Cancer Centre; Sir Charles Gairdner Hospital; Nedlands WA Australia
| | - M.P. Chu
- Clinician Scientist; Cross Cancer Institute; Edmonton Canada
| | - M. Dreyling
- Medizinische Klinik und Poliklinik III; Klinikum der Universität München, LMU München; München Germany
| | - I. Flinn
- Lymphoma Research; Sarah Cannon; Nashville United States
| | - L. Fogliatto
- Hematology; Irmandade da Santa Case de Misericórdia; Porto Alegre Brazil
| | - A. Goy
- Lymphoma Division; John Theurer Cancer Center, Hackensack University Medical Center; Hackensack United States
| | - D. Inwards
- Hematology; Mayo Clinic; Rochester United States
| | - W. Jurczak
- Department of Hematology; Jagiellonian University; Krakow Poland
| | - J. Mayer
- Hematology; Fakultní nemocnice Brno; Brno Czech Republic
| | - F. Re
- Hematology; Azienda Ospedaliero-Universitaria di Parma; Parma Italy
| | - T. Robak
- Hematology; Medical University of Lodz, Copernicus Memorial Hospital; Lodz Poland
| | - S. Spurgeon
- Hematology and Medical Oncology; OHSU Knight Cancer Institute; Portland United States
| | - S.S. Yoon
- Hemato Oncology; Seoul National University Hospital; Seoul Republic of Korea
| | - P.L. Zinzani
- Hematology; Institute of Hematology Seràgnoli, University of Bologna; Bologna Italy
| | - M. Yin
- Bio statistics; Acerta Pharma; South San Francisco United States
| | - T. Chen
- Clinical Development; Acerta Pharma; South San Francisco United States
| | | | | |
Collapse
|
7
|
Fraser G, Cramer P, Demirkan F, Silva RS, Grosicki S, Pristupa A, Janssens A, Mayer J, Bartlett NL, Dilhuydy MS, Pylypenko H, Loscertales J, Avigdor A, Rule S, Villa D, Samoilova O, Panagiotidis P, Goy A, Pavlovsky MA, Karlsson C, Hallek M, Mahler M, Salman M, Sun S, Phelps C, Balasubramanian S, Howes A, Chanan-Khan A. Updated results from the phase 3 HELIOS study of ibrutinib, bendamustine, and rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma. Leukemia 2019; 33:969-980. [PMID: 30315239 PMCID: PMC6484712 DOI: 10.1038/s41375-018-0276-9] [Citation(s) in RCA: 87] [Impact Index Per Article: 17.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/12/2018] [Revised: 05/09/2018] [Accepted: 08/28/2018] [Indexed: 12/21/2022]
Abstract
We report follow-up results from the randomized, placebo-controlled, phase 3 HELIOS trial of ibrutinib+bendamustine and rituximab (BR) for previously treated chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) without deletion 17p. Overall, 578 patients were randomized 1:1 to either ibrutinib (420 mg daily) or placebo, in combination with 6 cycles of BR, followed by ibrutinib or placebo alone. Median follow-up was 34.8 months (range: 0.1-45.8). Investigator-assessed median progression-free survival (PFS) was not reached for ibrutinib+BR, versus 14.3 months for placebo+BR (hazard ratio [HR] [95% CI], 0.206 [0.159-0.265]; P < 0.0001); 36-month PFS rates were 68.0% versus 13.9%, respectively. The results are consistent with the primary analysis findings (HR = 0.203, as assessed by independent review committee, with 17-month median follow-up). Median overall survival was not reached in either arm; HR (95% CI) for ibrutinib+BR versus placebo: 0.652 (0.454-0.935; P = 0.019). Minimal residual disease (MRD)-negative response rates were 26.3% for ibrutinib+BR and 6.2% for placebo+BR (P < 0.0001). Incidence of treatment-emergent adverse events (including grades 3-4) were generally consistent with the initial HELIOS report. These long-term data support improved survival outcomes and deepening responses with ibrutinib+BR compared with BR in relapsed CLL/SLL.
Collapse
Affiliation(s)
- G Fraser
- Juravinski Cancer Centre, McMaster University, Hamilton, ON, Canada.
| | - P Cramer
- Department of Internal Medicine, Center of Integrated Oncology and German CLL Study Group, University of Cologne, Cologne, Germany
| | - F Demirkan
- Division of Hematology, Dokuz Eylul University, Izmir, Turkey
| | - R Santucci Silva
- IEP São Lucas/Hemomed Oncologia e Hematologia, São Paulo, Brazil
| | - S Grosicki
- Department of Cancer Prevention, Faculty of Public Health, Silesian Medical University, Katowice, Poland
| | - A Pristupa
- Regional Clinical Hospital, Ryazan, Russia
| | - A Janssens
- Universitaire Ziekenhuizen Leuven, Leuven, Belgium
| | - J Mayer
- Department of Internal Medicine, Hematology and Oncology, Masaryk University Hospital Brno, Jihlavska, Brno, Czech Republic
| | - N L Bartlett
- Siteman Cancer Center, Washington University School of Medicine, St Louis, MO, USA
| | | | - H Pylypenko
- Department of Hematology, Cherkassy Regional Oncological Center, Cherkassy, Ukraine
| | - J Loscertales
- Hematology Department, Hospital Universitario La Princesa, IIS-IP, Madrid, Spain
| | - A Avigdor
- Division of Hematology and Bone Marrow Transplantation, Chaim Sheba Medical Center, Tel-Hashomer and Sackler School of Medicine, University of Tel-Aviv, Tel-Aviv, Israel
| | - S Rule
- Department of Haematology, Plymouth University Medical School, Plymouth, UK
| | - D Villa
- Division of Medical Oncology, British Columbia Cancer Agency, Vancouver, BC, Canada
| | - O Samoilova
- Nizhny Novogorod Regional Clinical Hospital, Nizhny Novogorod, Russia
| | - P Panagiotidis
- 1st Department of Propedeutic Medicine, National and Kapodistrian University of Athens, Athens, Greece
| | - A Goy
- John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, NJ, USA
| | - M A Pavlovsky
- Department of Hematology, Fundaleu, Buenos Aires, Argentina
| | - C Karlsson
- Department of Hematology, Karolinska University Hospital, Stockholm, Sweden
- Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden
| | - M Hallek
- Department I of Internal Medicine, University of Cologne, Cologne, Germany
| | - M Mahler
- Janssen Research & Development, Raritan, NJ, USA
| | - M Salman
- Janssen Research & Development, Raritan, NJ, USA
| | - S Sun
- Janssen Research & Development, Raritan, NJ, USA
| | - C Phelps
- Janssen Research & Development, Raritan, NJ, USA
| | | | - A Howes
- Janssen Research & Development, High Wycombe, UK
| | | |
Collapse
|
8
|
Mall S, Noakes J, Kossoff M, Lee W, McKessar M, Goy A, Duncombe J, Roberts M, Giuffre B, Miller A, Bhola N, Kapoor C, Shearman C, DaCosta G, Choi S, Sterba J, Kay M, Bruderlin K, Winarta N, Donohue K, Macdonell-Scott B, Klijnsma F, Suzuki K, Brennan P, Mello-Thoms C. Can digital breast tomosynthesis perform better than standard digital mammography work-up in breast cancer assessment clinic? Eur Radiol 2018; 28:5182-5194. [PMID: 29846804 DOI: 10.1007/s00330-018-5473-4] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/04/2018] [Revised: 03/24/2018] [Accepted: 04/10/2018] [Indexed: 11/30/2022]
Affiliation(s)
- S Mall
- Faculty of Health Sciences, University of Sydney, 75 East Street, Room M204, Lidcombe, New South Wales, Australia.
| | - J Noakes
- Northern Sydney & Central Coast BreastScreen, Royal North Shore Hospital, St. Leonards, New South Wales, Australia
| | - M Kossoff
- Northern Sydney & Central Coast BreastScreen, Royal North Shore Hospital, St. Leonards, New South Wales, Australia
| | - W Lee
- Northern Sydney & Central Coast BreastScreen, Royal North Shore Hospital, St. Leonards, New South Wales, Australia
| | - M McKessar
- Northern Sydney & Central Coast BreastScreen, Royal North Shore Hospital, St. Leonards, New South Wales, Australia
| | - A Goy
- Northern Sydney & Central Coast BreastScreen, Royal North Shore Hospital, St. Leonards, New South Wales, Australia
| | - J Duncombe
- Northern Sydney & Central Coast BreastScreen, Royal North Shore Hospital, St. Leonards, New South Wales, Australia
| | - M Roberts
- Northern Sydney & Central Coast BreastScreen, Royal North Shore Hospital, St. Leonards, New South Wales, Australia
| | - B Giuffre
- Northern Sydney & Central Coast BreastScreen, Royal North Shore Hospital, St. Leonards, New South Wales, Australia
| | - A Miller
- Northern Sydney & Central Coast BreastScreen, Royal North Shore Hospital, St. Leonards, New South Wales, Australia
| | - N Bhola
- Northern Sydney & Central Coast BreastScreen, Royal North Shore Hospital, St. Leonards, New South Wales, Australia
| | - C Kapoor
- Northern Sydney & Central Coast BreastScreen, Royal North Shore Hospital, St. Leonards, New South Wales, Australia
| | - C Shearman
- Northern Sydney & Central Coast BreastScreen, Royal North Shore Hospital, St. Leonards, New South Wales, Australia
| | - G DaCosta
- Northern Sydney & Central Coast BreastScreen, Royal North Shore Hospital, St. Leonards, New South Wales, Australia
| | - S Choi
- Northern Sydney & Central Coast BreastScreen, Royal North Shore Hospital, St. Leonards, New South Wales, Australia
| | - J Sterba
- Northern Sydney & Central Coast BreastScreen, Royal North Shore Hospital, St. Leonards, New South Wales, Australia
| | - M Kay
- Northern Sydney & Central Coast BreastScreen, Royal North Shore Hospital, St. Leonards, New South Wales, Australia
| | - K Bruderlin
- Northern Sydney & Central Coast BreastScreen, Royal North Shore Hospital, St. Leonards, New South Wales, Australia
| | - N Winarta
- Northern Sydney & Central Coast BreastScreen, Royal North Shore Hospital, St. Leonards, New South Wales, Australia
| | - K Donohue
- Northern Sydney & Central Coast BreastScreen, Royal North Shore Hospital, St. Leonards, New South Wales, Australia
| | - B Macdonell-Scott
- Northern Sydney & Central Coast BreastScreen, Royal North Shore Hospital, St. Leonards, New South Wales, Australia
| | - F Klijnsma
- Northern Sydney & Central Coast BreastScreen, Royal North Shore Hospital, St. Leonards, New South Wales, Australia
| | - K Suzuki
- Northern Sydney & Central Coast BreastScreen, Royal North Shore Hospital, St. Leonards, New South Wales, Australia
| | - P Brennan
- Faculty of Health Sciences, University of Sydney, 75 East Street, Room M204, Lidcombe, New South Wales, Australia
| | - C Mello-Thoms
- Faculty of Health Sciences, University of Sydney, 75 East Street, Room M204, Lidcombe, New South Wales, Australia
| |
Collapse
|
9
|
Mato AR, Hill BT, Lamanna N, Barr PM, Ujjani CS, Brander DM, Howlett C, Skarbnik AP, Cheson BD, Zent CS, Pu JJ, Kiselev P, Foon K, Lenhart J, Henick Bachow S, Winter AM, Cruz AL, Claxton DF, Goy A, Daniel C, Isaac K, Kennard KH, Timlin C, Fanning M, Gashonia L, Yacur M, Svoboda J, Schuster SJ, Nabhan C. Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multicenter study of 683 patients. Ann Oncol 2018; 28:1050-1056. [PMID: 28453705 DOI: 10.1093/annonc/mdx031] [Citation(s) in RCA: 167] [Impact Index Per Article: 27.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/12/2023] Open
Abstract
Background Ibrutinib, idelalisib, and venetoclax are approved for treating CLL patients in the United States. However, there is no guidance as to their optimal sequence. Patients and methods We conducted a multicenter, retrospective analysis of CLL patients treated with kinase inhibitors (KIs) or venetoclax. We examined demographics, discontinuation reasons, overall response rates (ORR), survival, and post-KI salvage strategies. Primary endpoint was progression-free survival (PFS). Results A total of 683 patients were identified. Baseline characteristics were similar in the ibrutinib and idelalisib groups. ORR to ibrutinib and idelalisib as first KI was 69% and 81%, respectively. With a median follow-up of 17 months (range 1-60), median PFS and OS for the entire cohort were 35 months and not reached. Patients treated with ibrutinib (versus idelalisib) as first KI had a significantly better PFS in all settings; front-line [hazard ratios (HR) 2.8, CI 1.3-6.3, P = 0.01], relapsed-refractory (HR 2.8, CI 1.9-4.1, P < 0.001), del17p (HR 2.0, CI 1.2-3.4, P = 0.008), and complex karyotype (HR 2.5, CI 1.2-5.2, P = 0.02). At the time of initial KI failure, use of an alternate KI or venetoclax had a superior PFS when compared with chemoimmunotherapy. Furthermore, patients who discontinued ibrutinib due to progression or toxicity had marginally improved outcomes if they received venetoclax (ORR 79%) versus idelalisib (ORR 46%) (PFS HR .6, CI.3-1.0, P = 0.06). Conclusions In the largest real-world experience of novel agents in CLL, ibrutinib appears superior to idelalisib as first KI. Furthermore, in the setting of KI failure, alternate KI or venetoclax therapy appear superior to chemoimmunotherapy combinations. The use of venetoclax upon ibrutinib failure might be superior to idelalisib. These data support the need for trials testing sequencing strategies to optimize treatment algorithms.
Collapse
Affiliation(s)
- A R Mato
- Center for CLL, Abramson Cancer Center, University of Pennsylvania, Philadelphia, USA
| | - B T Hill
- Taussig Cancer Institute, Cleveland Clinic, Cleveland, USA
| | - N Lamanna
- Division of Hematology and Oncology, New York Presbyterian/Columbia University Medical Center, New York, USA
| | - P M Barr
- Wilmot Cancer Institute, University of Rochester, Rochester, USA
| | - C S Ujjani
- Lombardi Comprehensive Cancer Center, Georgetown University Hospital, Washington, USA
| | | | - C Howlett
- Department of Pharmacy and Clinical Services, John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, USA.,Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, Piscataway, USA
| | - A P Skarbnik
- John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, USA
| | - B D Cheson
- Lombardi Comprehensive Cancer Center, Georgetown University Hospital, Washington, USA
| | - C S Zent
- Wilmot Cancer Institute, University of Rochester, Rochester, USA
| | - J J Pu
- Penn State Hershey Cancer Institute, Penn State University College of Medicine, Hershey, USA
| | | | - K Foon
- Celgene Corporation, Summit, USA
| | | | - S Henick Bachow
- Division of Hematology and Oncology, New York Presbyterian/Columbia University Medical Center, New York, USA
| | - A M Winter
- Taussig Cancer Institute, Cleveland Clinic, Cleveland, USA
| | - A-L Cruz
- Medstar Washington Hospital Center, Washington, USA
| | - D F Claxton
- Penn State Hershey Cancer Institute, Penn State University College of Medicine, Hershey, USA
| | - A Goy
- John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, USA
| | - C Daniel
- Center for CLL, Abramson Cancer Center, University of Pennsylvania, Philadelphia, USA
| | - K Isaac
- Center for CLL, Abramson Cancer Center, University of Pennsylvania, Philadelphia, USA
| | - K H Kennard
- Center for CLL, Abramson Cancer Center, University of Pennsylvania, Philadelphia, USA
| | - C Timlin
- Center for CLL, Abramson Cancer Center, University of Pennsylvania, Philadelphia, USA
| | - M Fanning
- Center for CLL, Abramson Cancer Center, University of Pennsylvania, Philadelphia, USA
| | - L Gashonia
- Center for CLL, Abramson Cancer Center, University of Pennsylvania, Philadelphia, USA
| | - M Yacur
- Penn State Hershey Cancer Institute, Penn State University College of Medicine, Hershey, USA
| | - J Svoboda
- Center for CLL, Abramson Cancer Center, University of Pennsylvania, Philadelphia, USA
| | - S J Schuster
- Center for CLL, Abramson Cancer Center, University of Pennsylvania, Philadelphia, USA
| | - C Nabhan
- Cardinal Health Specialty Solutions, Waukegan, USA
| |
Collapse
|
10
|
Harb W, Abramson J, Lunning M, Goy A, Maddocks K, Lebedinsky C, Senderowicz A, Trojer P, Bradley W, Flinn I. A phase 1 study of CPI-1205, a small molecule inhibitor of EZH2, preliminary safety in patients with B-cell lymphomas. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy048.001] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
11
|
Blum K, Abramson J, Maris M, Flinn I, Goy A, Mertz J, Sims R, Garner F, Senderowicz A, Younes A. A phase I study of CPI-0610, a bromodomain and extra terminal protein (BET) inhibitor in patients with relapsed or refractory lymphoma. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy048] [Citation(s) in RCA: 25] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
12
|
Younes A, Hilden P, Coiffier B, Hagenbeek A, Salles G, Wilson W, Seymour JF, Kelly K, Gribben J, Pfreunschuh M, Morschhauser F, Schoder H, Zelenetz AD, Rademaker J, Advani R, Valente N, Fortpied C, Witzig TE, Sehn LH, Engert A, Fisher RI, Zinzani PL, Federico M, Hutchings M, Bollard C, Trneny M, Elsayed YA, Tobinai K, Abramson JS, Fowler N, Goy A, Smith M, Ansell S, Kuruvilla J, Dreyling M, Thieblemont C, Little RF, Aurer I, Van Oers MHJ, Takeshita K, Gopal A, Rule S, de Vos S, Kloos I, Kaminski MS, Meignan M, Schwartz LH, Leonard JP, Schuster SJ, Seshan VE. International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017). Ann Oncol 2017; 28:1436-1447. [PMID: 28379322 PMCID: PMC5834038 DOI: 10.1093/annonc/mdx097] [Citation(s) in RCA: 200] [Impact Index Per Article: 28.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/24/2017] [Indexed: 12/20/2022] Open
Abstract
In recent years, the number of approved and investigational agents that can be safely administered for the treatment of lymphoma patients for a prolonged period of time has substantially increased. Many of these novel agents are evaluated in early-phase clinical trials in patients with a wide range of malignancies, including solid tumors and lymphoma. Furthermore, with the advances in genome sequencing, new "basket" clinical trial designs have emerged that select patients based on the presence of specific genetic alterations across different types of solid tumors and lymphoma. The standard response criteria currently in use for lymphoma are the Lugano Criteria which are based on [18F]2-fluoro-2-deoxy-D-glucose positron emission tomography or bidimensional tumor measurements on computerized tomography scans. These differ from the RECIST criteria used in solid tumors, which use unidimensional measurements. The RECIL group hypothesized that single-dimension measurement could be used to assess response to therapy in lymphoma patients, producing results similar to the standard criteria. We tested this hypothesis by analyzing 47 828 imaging measurements from 2983 individual adult and pediatric lymphoma patients enrolled on 10 multicenter clinical trials and developed new lymphoma response criteria (RECIL 2017). We demonstrate that assessment of tumor burden in lymphoma clinical trials can use the sum of longest diameters of a maximum of three target lesions. Furthermore, we introduced a new provisional category of a minor response. We also clarified response assessment in patients receiving novel immune therapy and targeted agents that generate unique imaging situations.
Collapse
Affiliation(s)
| | - P. Hilden
- Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, USA
| | - B. Coiffier
- Hematology, Université Lyon-1, Lyon-Sud Charles Mérieux, Lyon, France
| | - A. Hagenbeek
- Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
| | - G. Salles
- Hematology, Université Lyon-1, Lyon-Sud Charles Mérieux, Lyon, France
| | - W. Wilson
- Lymphoid Malignancies Branch, National Cancer Institute, Bethesda, USA
| | - J. F. Seymour
- Peter MacCallum Cancer Centre and University of Melbourne, Australia
| | - K. Kelly
- Pediatrics Department, Roswell-Park Cancer Institute, Buffalo, USA
| | - J. Gribben
- Department of Haemato-Oncology, Barts Cancer Institute, London, UK
| | - M. Pfreunschuh
- Department of Internal Medicine, Universität des Saarlandes, Homburg, Germany
| | - F. Morschhauser
- Department of Hematology, Université de Lille 2, Lille, France
| | - H. Schoder
- Department of Radiology, Memorial Sloan-Kettering Cancer Center, New York
| | | | - J. Rademaker
- Department of Radiology, Memorial Sloan-Kettering Cancer Center, New York
| | - R. Advani
- Department of Oncology, Stanford University, Stanford
| | | | | | | | - L. H. Sehn
- British Columbia Cancer Agency, Vancouver, Canada
| | - A. Engert
- Department of Internal Medicine, University Hospital of Cologne, Cologne, Germany
| | | | - P.-L. Zinzani
- Department of Hematology, University of Bologna, Bologna
| | - M. Federico
- Department of Diagnostic Medicine, University of Modena, Modena, Italy
| | - M. Hutchings
- Department of Hematology, University of Copenhagen, Denmark
| | - C. Bollard
- Children’s National Health System, Washington, USA
| | - M. Trneny
- Lymphoma and Stem Cell Transplantation Program, Charles University, Prague, Czech Republic
| | | | - K. Tobinai
- Department of Hematology, National Cancer Center Hospital, Tokyo, Japan
| | - J. S. Abramson
- Massachusetts General Hospital, Center for Lymphoma, Boston
| | - N. Fowler
- U.T. M.D.Anderson Cancer Center, Houston
| | - A. Goy
- John Theurer Cancer Center, Hackensack University Medical Center, Hackensack
| | - M. Smith
- Cleveland Clinic, Cleveland, USA
| | | | - J. Kuruvilla
- Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Canada
| | - M. Dreyling
- Medicine Clinic III, Ludwig Maximilian University, Munich, Germany
| | | | - R. F. Little
- Divisions of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, USA
| | - I. Aurer
- Department of Hematology, University Hospital Centre Zagreb, Zagreb, Croatia
| | | | | | - A. Gopal
- Fred Hutchinson Cancer Research Center, Seattle, USA
| | - S. Rule
- Haematology Department, Plymouth University, UK
| | | | - I. Kloos
- Servier, Neuilly sur Seine, France
| | - M. S. Kaminski
- University of Michigan Comprehensive Cancer Center, Ann Arbor, USA
| | - M. Meignan
- Nuclear Medicine, Hôpitaux Universitaires Henri Mondor, Créteil, France
| | - L. H. Schwartz
- Columbia University College of Physicians and Surgeons and New York Presbyterian Hospital, New York
| | - J. P. Leonard
- Weill Cornell Medicine and and New York Presbyterian Hospital, New York
| | - S. J. Schuster
- University of Pennsylvania School of Medicine, Philadelphia, USA
| | - V. E. Seshan
- Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, USA
| |
Collapse
|
13
|
Cramer P, Demirkan F, Fraser G, Pristupa A, Bartlett N, Dilhuydy M, Loscertales J, Avigdor A, Rule S, Samoilova O, Goy A, Ganguly S, Poggesi I, Lavezzi S, De Nicolao G, de Jong J, Neyens M, Salman M, Howes A, Mahler M. IBRUTINIB INCREASES THE SYSTEMIC EXPOSURE OF RITUXIMAB: PHARMACOKINETIC RESULTS FROM THE HELIOS TRIAL. Hematol Oncol 2017. [DOI: 10.1002/hon.2438_95] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- P. Cramer
- Department I of Internal Medicine and German CLL Study Group; University Hospital of Cologne; Cologne Germany
| | - F. Demirkan
- Hematology; Dokuz Eylul University; Izmir Turkey
| | - G. Fraser
- Oncology; McMaster University, Juravinski Cancer Centre; Hamilton Canada
| | - A. Pristupa
- Hematology; Ryazan Regional Clinical Hospital; Ryazan Russian Federation
| | - N. Bartlett
- Medicine; Washington University School of Medicine, Siteman Cancer Center; St. Louis USA
| | - M. Dilhuydy
- Hematology and Cell Therapy, Hôpital Haut-Lévèque; Bordeaux France
| | - J. Loscertales
- Hematology; Hospital Universitario de La Princesa, IIS-IP; Madrid Spain
| | - A. Avigdor
- Hematology and Bone-Marrow Transplantation, Chaim Sheba Medical Center; Tel Hashomer Israel
| | - S. Rule
- Haematology; Derriford Hospital; Plymouth UK
| | - O. Samoilova
- Hematology; Nizhny Novgorod Regional Clinical Hospital; Nizhny Novgorod Russian Federation
| | - A. Goy
- Lymphoma; John Theurer Cancer Center at Hackensack University Medical Center; Hackensack USA
| | - S. Ganguly
- Hematologic Malignancies and Cellular Therapeutics; University of Kansas Medical Center; Kansas City USA
| | - I. Poggesi
- Clinical Pharmacology, Janssen R&D; Cologno Monzese Italy
| | - S.M. Lavezzi
- Electrical, Computer, and Biomedical Engineering, University of Pavia; Pavia Italy
| | - G. De Nicolao
- Electrical, Computer, and Biomedical Engineering, University of Pavia; Pavia Italy
| | - J. de Jong
- Clinical Pharmacology, Janssen R&D; San Diego USA
| | - M. Neyens
- Clinical Pharmacology-Pharmacometrics, Janssen R&D; Beerse Belgium
| | - M. Salman
- Clinical Oncology, Janssen R&D; Raritan USA
| | - A. Howes
- Clinical Oncology, Janssen R&D; High Wycombe UK
| | - M. Mahler
- Clinical Oncology, Janssen R&D; Raritan USA
| |
Collapse
|
14
|
Neelapu S, Locke F, Bartlett N, Siddiqi T, Braunschweig I, Lekakis L, Goy A, Castro J, Oluwole O, Miklos D, Timmerman J, Jacobson C, Reagan P, Flinn I, Farooq U, Stiff P, Navale L, Elias M, Wiezorek J, Go W. ZUMA-1: A phase 2 multi-center study evaluating anti-CD19 chimeric antigen receptor (CAR) T cells in patients with refractory aggressive non-Hodgkin lymphoma (NHL). Ann Oncol 2016. [DOI: 10.1093/annonc/mdw375.38] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
15
|
Czuczman MS, Goy A, Lamonica D, Graf DA, Munteanu MC, van der Jagt RH. Phase II study of bendamustine combined with rituximab in relapsed/refractory mantle cell lymphoma: efficacy, tolerability, and safety findings. Ann Hematol 2015; 94:2025-32. [PMID: 26411584 DOI: 10.1007/s00277-015-2478-9] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/07/2015] [Accepted: 08/11/2015] [Indexed: 01/06/2023]
Abstract
In most cases of relapsed/refractory mantle cell lymphoma (MCL), patients respond to salvage therapy, though typically responses are partial and/or transient followed by disease progression, even with newer agents (e.g., ibrutinib). In this multicenter, open-label, single-arm, phase II study, patients with relapsed/refractory non-blastoid MCL received bendamustine 90 mg/m(2) (days 1 and 2) and rituximab 375 mg/m(2) (day 1) for 6 planned 28-day cycles. Functional imaging with 18-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography (18F-FDG PET/CT) was conducted at baseline and after cycle 6. Forty-five patients were enrolled (median age, 70 years; 82 % stage IV disease; median number of prior chemotherapies, 2 [range, 1-4]), showing an overall response rate (ORR; primary efficacy measure) of 82 % (complete response [CR], 40 %; partial response, 42 %). In the 32 patients with complete 18F-FDG PET/CT data, 75 % achieved a complete metabolic response. Median duration of response was 1.6 years, 1-year progression-free survival was 67 %, and 3-year overall survival was 55 %. Main non-hematologic adverse events were nausea (69 %), fatigue (56 %), decreased appetite (42 %), constipation (38 %), diarrhea (36 %), vomiting (36 %), and decreased weight (31 %). Grade 3/4 neutropenia and lymphopenia occurred in 44 and 89 % of patients, respectively. ORR and CR rate compared favorably with single-agent ibrutinib (ORR, 67 %; CR, 23 %); bendamustine-rituximab is an effective therapy with manageable toxicity in relapsed/refractory MCL.
Collapse
Affiliation(s)
- Myron S Czuczman
- Department of Medicine, Elm and Carlton Streets, Roswell Park Cancer Institute, Buffalo, NY, 14263, USA.
| | - A Goy
- Lymphoma Division, Hackensack University Medical Center, Hackensack, NJ, 07601, USA
| | - D Lamonica
- Department of Nuclear Medicine, Roswell Park Cancer Institute, Buffalo, NY, 14263, USA
| | - D A Graf
- Department of Nuclear Medicine, Roswell Park Cancer Institute, Buffalo, NY, 14263, USA.,University of Texas Medical Branch at Galveston, Galveston, TX, 77555, USA
| | - M C Munteanu
- Teva Branded Pharmaceutical Products R&D, Inc., Frazer, PA, 19355, USA
| | - R H van der Jagt
- Department of Medicine, The Ottawa Hospital, General Campus, K1H 8L6, Ottawa, Canada
| |
Collapse
|
16
|
Witzig T, Nowakowski G, Habermann T, Goy A, Hernandez-Ilizaliturri F, Chiappella A, Vitolo U, Fowler N, Czuczman M. A comprehensive review of lenalidomide therapy for B-cell non-Hodgkin lymphoma. Ann Oncol 2015; 26:1667-77. [DOI: 10.1093/annonc/mdv102] [Citation(s) in RCA: 73] [Impact Index Per Article: 8.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/29/2014] [Accepted: 02/10/2015] [Indexed: 12/26/2022] Open
|
17
|
Abramson JS, Feldman T, Kroll-Desrosiers AR, Muffly LS, Winer E, Flowers CR, Lansigan F, Nabhan C, Nastoupil LJ, Nath R, Goy A, Castillo JJ, Jagadeesh D, Woda B, Rosen ST, Smith SM, Evens AM. Peripheral T-cell lymphomas in a large US multicenter cohort: prognostication in the modern era including impact of frontline therapy. Ann Oncol 2014; 25:2211-2217. [PMID: 25193992 DOI: 10.1093/annonc/mdu443] [Citation(s) in RCA: 97] [Impact Index Per Article: 9.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/14/2023] Open
Abstract
BACKGROUND Optimal frontline therapy for peripheral T-cell lymphoma (PTCL) in the modern era remains unclear. PATIENTS AND METHODS We examined patient characteristics, treatment, and outcomes among 341 newly diagnosed PTCL patients from 2000 to 2011. Outcome was compared with a matched cohort of diffuse large B-cell lymphoma (DLBCL) patients, and prognostic factors were assessed using univariate and multivariate analyses. RESULTS PTCL subtypes included PTCL, not otherwise specified (PTCL-NOS) (31%), anaplastic large T-cell lymphoma (ALCL) (26%), angioimmunoblastic T-cell lymphoma (23%), NK/T-cell lymphoma (7%), acute T-cell leukemia/lymphoma (6%), and other (7%). Median age was 62 years (range 18-95 years), and 74% had stage III-IV disease. Twenty-three (7%) patients received only palliative care whereas 318 received chemotherapy: CHOP-like regimens (70%), hyperCVAD/MA (6%), or other (18%). Thirty-three patients (10%) underwent stem-cell transplantation (SCT) in first remission. The overall response rate was 73% (61% complete); 24% had primary refractory disease. With 39-month median follow-up, 3-year progression-free survival (PFS) and overall survival (OS) were 32% and 52%. PFS and OS for PTCL patients were significantly inferior to matched patients with DLBCL. On multivariate analysis, stage I-II disease was the only significant pretreatment prognostic factor [PFS: hazard ratio (HR) 0.54, 95% confidence interval (CI) 0.34-0.85, P = 0.007; OS: HR 0.42, 95% CI 0.22-0.78, P = 0.006]. ALK positivity in ALCL was prognostic on univariate analysis, but lost significance on multivariate analysis. The most dominant prognostic factor was response to initial therapy (complete response versus other), including adjustment for stage and SCT [PFS: HR 0.19, 95% CI 0.14-0.28, P < 0.0001; OS: HR 0.26, 95% CI 0.17-0.40, P < 0.0001]. No overall survival difference was observed based on choice of upfront regimen or SCT in first remission. CONCLUSIONS This analysis identifies early-stage disease and initial treatment response as dominant prognostic factors in PTCL. No clear benefit was observed for patients undergoing consolidative SCT. Novel therapeutic approaches for PTCL are critically needed.
Collapse
Affiliation(s)
- J S Abramson
- Center for Lymphoma, Massachusetts General Hospital Cancer Center, Boston
| | - T Feldman
- John Theurer Cancer Center, Hackensack University Medical Center, Hackensack
| | - A R Kroll-Desrosiers
- Department of Hematology/Oncology, University of Massachusetts Medical School, Worcester
| | - L S Muffly
- Department of Hematology/Oncology, University of Chicago, Chicago
| | - E Winer
- Department of Hematology/Oncology, Rhode Island Hospital, Providence
| | - C R Flowers
- Department of Hematology/Oncology, Emory University School of Medicine, Atlanta
| | - F Lansigan
- Department of Hematology/Oncology, Dartmouth-Hitchcock Medical Center, Lebanon
| | - C Nabhan
- Department of Hematology/Oncology, University of Chicago, Chicago
| | - L J Nastoupil
- Department of Hematology/Oncology, Emory University School of Medicine, Atlanta
| | - R Nath
- Department of Hematology/Oncology, University of Massachusetts Medical School, Worcester
| | - A Goy
- John Theurer Cancer Center, Hackensack University Medical Center, Hackensack
| | - J J Castillo
- Department of Hematology/Oncology, Miriam Hospital, Providence
| | - D Jagadeesh
- Department of Hematology/Oncology, University of Massachusetts Medical School, Worcester
| | - B Woda
- Department of Hematology/Oncology, University of Massachusetts Medical School, Worcester
| | - S T Rosen
- Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago
| | - S M Smith
- Department of Hematology/Oncology, University of Chicago, Chicago
| | - A M Evens
- Department of Hematology/Oncology, Tufts Medical Center, Boston, USA.
| |
Collapse
|
18
|
Kuo PY, Leshchenko VV, Fazzari MJ, Perumal D, Gellen T, He T, Iqbal J, Baumgartner-Wennerholm S, Nygren L, Zhang F, Zhang W, Suh KS, Goy A, Yang DT, Chan WC, Kahl BS, Verma AK, Gascoyne RD, Kimby E, Sander B, Ye BH, Melnick AM, Parekh S. High-resolution chromatin immunoprecipitation (ChIP) sequencing reveals novel binding targets and prognostic role for SOX11 in mantle cell lymphoma. Oncogene 2014; 34:1231-40. [PMID: 24681958 DOI: 10.1038/onc.2014.44] [Citation(s) in RCA: 49] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/01/2013] [Revised: 01/07/2014] [Accepted: 01/19/2014] [Indexed: 12/18/2022]
Abstract
Sex determining region Y-box 11 (SOX11) expression is specific for mantle cell lymphoma (MCL) as compared with other non-Hodgkin's lymphomas. However, the function and direct-binding targets of SOX11 in MCL are largely unknown. We used high-resolution chromatin immunoprecipitation sequencing to identify the direct target genes of SOX11 in a genome-wide, unbiased manner and elucidate its functional significance. Pathway analysis identified WNT, PKA and TGF-beta signaling pathways as significantly enriched by SOX11-target genes. Quantitative chromatin immunoprecipitation sequencing and promoter reporter assays confirmed that SOX11 directly binds to individual genes and modulates their transcription activities in these pathways in MCL. Functional studies using RNA interference demonstrate that SOX11 directly regulates WNT in MCL. We analyzed SOX11 expression in three independent well-annotated tissue microarrays from the University of Wisconsin (UW), Karolinska Institute and British Columbia Cancer Agency. Our findings suggest that high SOX11 expression is associated with improved survival in a subset of MCL patients, particularly those treated with intensive chemotherapy. Transcriptional regulation of WNT and other biological pathways affected by SOX11-target genes may help explain the impact of SOX11 expression on patient outcomes.
Collapse
Affiliation(s)
- P-Y Kuo
- Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - V V Leshchenko
- Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - M J Fazzari
- 1] Department of Population Health, Albert Einstein College of Medicine of Yeshiva University, Bronx, NY, USA [2] Department of Genetics, Albert Einstein College of Medicine of Yeshiva University, Bronx, NY, USA
| | - D Perumal
- Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - T Gellen
- Albert Einstein Cancer Center, Albert Einstein College of Medicine of Yeshiva University, Bronx, NY, USA
| | - T He
- Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - J Iqbal
- Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE, USA
| | - S Baumgartner-Wennerholm
- Department of Medicine, Center for Haematology, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden
| | - L Nygren
- Department of Laboratory Medicine, Division of Pathology, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden
| | - F Zhang
- Bioinformatics Laboratory, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - W Zhang
- Bioinformatics Laboratory, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - K S Suh
- Genomics and Biomarkers Program, John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ, USA
| | - A Goy
- Genomics and Biomarkers Program, John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ, USA
| | - D T Yang
- Department of Pathology, School of Medicine and Public Health, University of Wisconsin, Madison, WI, USA
| | - W-C Chan
- Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE, USA
| | - B S Kahl
- Department of Medicine, School of Medicine and Public Health, and The UW Carbone Cancer Center, University of Wisconsin, Madison, WI, USA
| | - A K Verma
- Albert Einstein Cancer Center, Albert Einstein College of Medicine of Yeshiva University, Bronx, NY, USA
| | - R D Gascoyne
- Department of Pathology and Experimental Therapeutics, British Columbia Cancer Agency, Vancouver, British Columbia, Canada
| | - E Kimby
- Department of Medicine, Center for Haematology, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden
| | - B Sander
- Department of Laboratory Medicine, Division of Pathology, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden
| | - B H Ye
- Department of Cell Biology, Albert Einstein College of Medicine of Yeshiva University, Bronx, NY, USA
| | - A M Melnick
- 1] Hematology and Oncology Division, Weill Cornell Medical College, New York, NY, USA [2] Department of Pharmacology, Weill Cornell Medical College, New York, NY, USA
| | - S Parekh
- Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| |
Collapse
|
19
|
Straus DJ, Duvic M, Horwitz SM, Hymes K, Goy A, Hernandez-Ilizaliturri FJ, Feldman T, Wegner B, Myskowski PL. Final results of phase II trial of doxorubicin HCl liposome injection followed by bexarotene in advanced cutaneous T-cell lymphoma. Ann Oncol 2013; 25:206-10. [PMID: 24285015 DOI: 10.1093/annonc/mdt480] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
BACKGROUND High response rates for doxorubicin HCl liposome injection (DLI) in cutaneous T-cell lymphoma (CTCL) have been reported with vague criteria until recently. Approximately 50% of CTCL patients respond to bexarotene (Bex). PATIENTS AND METHODS A phase II trial was carried out to clarify the true overall response rate (ORR) for DLI and to assess the role of sequential Bex. Patients were treated with DLI 20 mg/m(2) i.v. every 2 weeks for 16 weeks (8 doses) followed by 16 weeks with Bex 300 mg/m(2) orally. Response assessments were carried out after 16 (DLI) and 32 weeks (Bex). Skin responses were measured by the modified Severity-Weighted Assessment Tool (mSWAT) and the Composite Assessment of Index Lesion Severity (CA). RESULTS Thirty-seven patients were treated: stage IV (22, 8 with Sézary syndrome), IIB (10), earlier stage refractory to skin-directed therapies or radiation therapy (5). For 34 assessable patients: ORR 14/34 [41%: partial response (PR) 12, clinical complete response (CCR) 2]. Maximum responses were all seen after 16 weeks DLI. Median progression-free survival (PFS) was 5 months. There were 22 deaths: 21 of disease and 1 of heart failure. Twenty-seven grade 3 and 5 grade 4 toxic events were observed. CONCLUSION(S) With strict criteria, DLI ORR is among the highest reported for single agents in CTCL. Sequential Bex did not increase the response rate or duration.
Collapse
Affiliation(s)
- D J Straus
- Department of Medicine, Division of Hematologic Oncology, Lymphoma Service, Memorial Sloan-Kettering Cancer Center, New York
| | | | | | | | | | | | | | | | | |
Collapse
|
20
|
Gharbaran R, Park J, Kim C, Goy A, Suh KS. Circulating tumor cells in Hodgkin's lymphoma - a review of the spread of HL tumor cells or their putative precursors by lymphatic and hematogenous means, and their prognostic significance. Crit Rev Oncol Hematol 2013; 89:404-17. [PMID: 24176672 DOI: 10.1016/j.critrevonc.2013.09.004] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/26/2013] [Revised: 08/26/2013] [Accepted: 09/20/2013] [Indexed: 01/05/2023] Open
Abstract
About 15% of patients diagnosed with classical Hodgkin's lymphoma (cHL) are considered high risk with unfavorable prognosis. The biology of the disease bears a direct relationship to its clinical course. However, some aspects of the disease are still being debated. Related topics include origin of neoplastic cells as circulating precursor versus germinal center B cell, and disease metastasis via hematogenous routes and the effect of HL circulation on relapse potential and further spread of the disease. The terminally differentiated giant neoplastic Hodgkin Reed-Sternberg (HRS) cells (HRSC) have limited proliferation and lack mobility. Therefore, they are unable to penetrate epithelium. Thus, the clinical aggressiveness of HRSCs that disseminate via both lymphatic and hematogenous may be determined by their molecular composition. This review discusses in detail the historical perspectives on scientific and clinical evidences of precursors of circulating HL cells and the prognostic importance of these circulating cells for predicting outcome.
Collapse
Affiliation(s)
- Rajendra Gharbaran
- The Genomics and Biomarkers Program, The John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ 07601, United States
| | - Jongwhan Park
- The Genomics and Biomarkers Program, The John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ 07601, United States
| | - Chris Kim
- The Genomics and Biomarkers Program, The John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ 07601, United States
| | - A Goy
- Lymphoma Division, The John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ 07601, United States
| | - K Stephen Suh
- The Genomics and Biomarkers Program, The John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ 07601, United States.
| |
Collapse
|
21
|
Ogura M, Leach J, Egyed M, Ando K, Hatake K, Tobinai K, Feldman T, Hua S, Volkert A, Vandendries E, Goy A. Inotuzumab Ozogamicin in B-Cell Non-Hodgkin's Lymphoma Refractory to Rituximab + Chemotherapy or Radioimmunotherapy. Ann Oncol 2012. [DOI: 10.1016/s0923-7534(20)32235-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
22
|
Mato AR, Feldman T, Zielonka T, Goldberg S, Rowley SD, Donato M, Siegel DSD, Vesole DH, Campaiola A, Facchin K, Stives S, Bejot C, Curtin M, Miller M, Agress H, Panush D, Lizotte P, Pecora A, Bhattacharyya P, Goy A. A new predictive model based on age, pretreatment LDH, and post-therapy PET-CT in patients with MCL treated with dose-intensive strategies. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.8051] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
23
|
Feldman T, Mato AR, Zielonka T, Rowley SD, Goldberg S, Donato M, Siegel DSD, Facchin K, Campaiola A, Vesole DH, Bejot C, Stives S, Curtin M, Miller M, Agress H, Panush D, Lizotte P, Bhattacharyya P, Pecora A, Goy A. The association between the GOELAMS MCL-PET prognostic index and survival in patients treated with rituximab-hypercvad (R-HyCVAD) or high-dose therapy with autologous stem cell rescue (HDT/ASCT). J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.8050] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
24
|
Awan FT, Pagel JM, Goy A, Rifkin RM, Poiesz BJ, Mato AR, Stromatt SC, Byrd JC, Jaeger U. A phase Ib/II open-label study to evaluate the safety and efficacy of TRU-016 in combination with bendamustine versus bendamustine alone in patients with relapsed chronic lymphocytic leukemia. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.e13053] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
25
|
Fowler D, Mossoba M, Hakim F, Kurlander R, Gea-Banacloche J, Sportes C, Hardy N, Pavletic S, Steinberg S, Khuu H, Sabatino M, Stroncek D, Leitman S, Rowley S, Donato M, Goy A, Friedman T, Korngold R, Pecora A, Levine B, June C, Gress R, Bishop M. T-Rapa Cell DLI Safely Balances Th1/Th2 Cytokine Activation After Low-Intensity Allogeneic Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant 2011. [DOI: 10.1016/j.bbmt.2010.12.023] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
26
|
Feldman T, Mato AR, Zielonka T, Masood A, Goldberg S, Rowley SD, Donato M, Siegel DS, Pecora A, Goy A. Effect of front-line therapy with either high-dose therapy and autologous stem cell rescue (HDT/ASCR) or dose-intensive therapy (R-Hypercvad) on outcome in mantle cell lymphoma (MCL). J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.8067] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
27
|
Mato AR, Zielonka T, Feldman T, Bhattacharyya P, Bejot C, George N, Stives S, Goldberg S, Pecora A, Goy A. The association between the Mantle Cell Lymphoma International Prognostic Index (MIPI) and survival in patients treated with rituximab-HCVAD (RHCVAD) alternating with rituximab-methotrexate-AraC (R-MTX-AraC). J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.8092] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
28
|
Straus DJ, Duvic M, Horwitz SM, Hymes KB, Goy A, Hernandez-Ilizaliturri FJ, Feldman T, Wegner B, Myskowski P. Interim results of phase II trial of pegylated liposomal doxorubicin (PLD) followed by bexarotene in advanced cutaneous T-cell lymphoma (CTCL). J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.8053] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
29
|
Hernandez-Ilizaliturri FJ, Deeb G, Zinzani PL, Pileri SA, Malik F, Macon WR, Witzig TE, Goy A, Czuczman MS. Response of relapsed/refractory diffuse large B-cell lymphoma (DLBCL) with nongerminal center B-cell phenotype to lenalidomide (L) alone or in combination with rituximab (R). J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.8038] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
30
|
Manoukian GE, Hagemeister FB, McLaughlin P, Fayad L, Samaniego F, Goy A, Romaguera JE, Pro B, Cabanillas F, Rodriguez MA. Rituximab, fludarabine, mitoxantrone, and dexamethasone (R-FND) for patients with relapsed indolent B-cell lymphoma (RIL). J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.8078] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
31
|
Foss FM, Sjak-Shie NN, Goy A, Advani R, Jacobsen ED. Phase II study of denileukin diftitox with CHOP chemotherapy in newly-diagnosed PTCL: CONCEPT trial. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.8045] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
32
|
Goy A, Bernstein SH, Kahl BS, Djulbegovic B, Robertson MJ, de Vos S, Epner E, Krishnan A, Leonard JP, Lonial S, Nasta S, O'Connor OA, Shi H, Boral AL, Fisher RI. Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study. Ann Oncol 2009; 20:520-5. [PMID: 19074748 PMCID: PMC4592328 DOI: 10.1093/annonc/mdn656] [Citation(s) in RCA: 268] [Impact Index Per Article: 17.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/01/2008] [Revised: 08/27/2008] [Accepted: 09/03/2008] [Indexed: 11/12/2022] Open
Abstract
BACKGROUND We previously reported results of the phase 2, multicenter PINNACLE study, which confirmed the substantial single-agent activity of bortezomib in patients with relapsed or refractory mantle cell lymphoma (MCL). MATERIALS AND METHODS We report updated time-to-event data, in all patients and by response to treatment, after extended follow-up (median 26.4 months). RESULTS Median time to progression (TTP) was 6.7 months. Median time to next therapy (TTNT) was 7.4 months. Median overall survival (OS) was 23.5 months. In responding patients, median TTP was 12.4 months, median duration of response (DOR) was 9.2 months, median TTNT was 14.3 months, and median OS was 35.4 months. Patients achieving complete response had heterogeneous disease characteristics; among these patients, median TTP and DOR were not reached, and median OS was 36.0 months. One-year survival rate was 69% overall and 91% in responding patients. Median OS from diagnosis was 61.1 months, after median follow-up of 63.7 months. Activity was seen in patients with refractory disease and patients relapsing following high-intensity treatment. Toxicity was generally manageable. CONCLUSIONS Single-agent bortezomib is associated with lengthy responses and notable survival in patients with relapsed or refractory MCL, with considerable TTP and TTNT in responding patients, suggesting substantial clinical benefit.
Collapse
Affiliation(s)
- A Goy
- The Cancer Center at Hackensack University Medical Center, Hackensack, NJ 07601, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
33
|
Buccafurri F, De Meo P, Fugini M, Furnari R, Goy A, Lax G, Lops P, Modafferi S, Pernici B, Redavid D, Semeraro G, Ursino D. Analysis of QoS in cooperative services for real time applications. DATA KNOWL ENG 2008. [DOI: 10.1016/j.datak.2008.08.004] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
34
|
O’Connor OA, Goy A, Orlowski R, Hainsworth JD, Leonard JP, Afanasyev B, Osmanov D, Chen M, Wolff A. A phase I-II trial of the kinesin spindle protein (KSP) inhibitor SB-743921 on days 1 and 15 every 28 days in non-Hodgkin or Hodgkin lymphoma. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.8539] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
35
|
Stewart KA, O’Connor OA, Alsina M, Trudel S, Urquilla PR, Vallone MK, Molineaux CJ, Goy A, Orlowski RZ. Phase I evaluation of carfilzomib (PR-171) in hematological malignancies: Responses in multiple myeloma and Waldenstrom’s macroglobulinemia at well-tolerated doses. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.8003] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
8003 Background: Carfilzomib is a novel, irreversible tetrapeptide proteasome inhibitor derived from the natural product epoxomicin. Carfilzomib was well tolerated in preclinical animal studies when administered on a two-week cycle, QDx5; proteasome inhibition one hour after dosing at the MTD was >80%. Two Phase I dose-escalation studies are ongoing, aimed at determining the safety, tolerability, and biological response to carfilzomib. Methods: Carfilzomib was administered according to two different dose-intensive schedules. In PX-171–001, carfilzomib was administered on a two week cycle, QDx5 with nine days rest; in PX-171–002, carfilzomib was administered on a four week cycle, QDx2 weekly for three weeks with 12 days rest. Eligible patients have multiple myeloma (MM), Non-Hodgkin's Lymphoma (NHL), Hodgkin's Disease (HD), or Waldenström's Macroglobulinemia (WM). Results: Thus far, a total of 54 subjects have been enrolled. Although the maximum tolerated dose (MTD) has not yet been identified on either study, responses seen on both protocols have established 11 and 15 mg/m2 as the minimal effective doses (MEDs) on PX-171–001 and 002, respectively. Of 3 patients with MM or WM treated on the 001 protocol, one MM patient has had a Partial Response (PR) and one WM patient had a Minimal Response (MR). Of 8 patients with MM treated on the 002 protocol, 3 patients have had PRs. 6 additional patients have had Stable Disease lasting longer than 6 months and symptomatic improvement has been seen in patients on both protocols. 11 subjects remain on study with stable disease or better. Proteasome inhibition in whole blood at the highest dose levels exceeded 80% one hour after the first dose. Carfilzomib has been well tolerated at doses at and above the MED thus far. There has been no incidence of painful peripheral neuropathy on either study. No dose-limiting toxicities (DLTs) have occurred on PX-171–001; one DLT (Gr 4 anemia and thrombocytopenia) was observed at 27 mg/m2 on PX-171–002. Conclusions: Thus far, intensive dosing with carfilzomib is well-tolerated at proteasome inhibition levels of more than 80%. Five responses have been observed, and several subjects have achieved long lasting SD and/or symptomatic improvement. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- K. A. Stewart
- Mayo Clinic Arizona, Scottsdale, AZ; Memorial Sloan-Kettering Cancer Center, New York, NY; H. Lee Moffitt Cancer Center, Tampa, FL; Princess Margaret Hospital, Toronto, ON, Canada; Proteolix, South San Francisco, CA; Proteolix, Inc., South San Francisco, CA; Hackensack University Medical Center, Hackensack, NJ; University of North Carolina, Chapel Hill, NC
| | - O. A. O’Connor
- Mayo Clinic Arizona, Scottsdale, AZ; Memorial Sloan-Kettering Cancer Center, New York, NY; H. Lee Moffitt Cancer Center, Tampa, FL; Princess Margaret Hospital, Toronto, ON, Canada; Proteolix, South San Francisco, CA; Proteolix, Inc., South San Francisco, CA; Hackensack University Medical Center, Hackensack, NJ; University of North Carolina, Chapel Hill, NC
| | - M. Alsina
- Mayo Clinic Arizona, Scottsdale, AZ; Memorial Sloan-Kettering Cancer Center, New York, NY; H. Lee Moffitt Cancer Center, Tampa, FL; Princess Margaret Hospital, Toronto, ON, Canada; Proteolix, South San Francisco, CA; Proteolix, Inc., South San Francisco, CA; Hackensack University Medical Center, Hackensack, NJ; University of North Carolina, Chapel Hill, NC
| | - S. Trudel
- Mayo Clinic Arizona, Scottsdale, AZ; Memorial Sloan-Kettering Cancer Center, New York, NY; H. Lee Moffitt Cancer Center, Tampa, FL; Princess Margaret Hospital, Toronto, ON, Canada; Proteolix, South San Francisco, CA; Proteolix, Inc., South San Francisco, CA; Hackensack University Medical Center, Hackensack, NJ; University of North Carolina, Chapel Hill, NC
| | - P. R. Urquilla
- Mayo Clinic Arizona, Scottsdale, AZ; Memorial Sloan-Kettering Cancer Center, New York, NY; H. Lee Moffitt Cancer Center, Tampa, FL; Princess Margaret Hospital, Toronto, ON, Canada; Proteolix, South San Francisco, CA; Proteolix, Inc., South San Francisco, CA; Hackensack University Medical Center, Hackensack, NJ; University of North Carolina, Chapel Hill, NC
| | - M. K. Vallone
- Mayo Clinic Arizona, Scottsdale, AZ; Memorial Sloan-Kettering Cancer Center, New York, NY; H. Lee Moffitt Cancer Center, Tampa, FL; Princess Margaret Hospital, Toronto, ON, Canada; Proteolix, South San Francisco, CA; Proteolix, Inc., South San Francisco, CA; Hackensack University Medical Center, Hackensack, NJ; University of North Carolina, Chapel Hill, NC
| | - C. J. Molineaux
- Mayo Clinic Arizona, Scottsdale, AZ; Memorial Sloan-Kettering Cancer Center, New York, NY; H. Lee Moffitt Cancer Center, Tampa, FL; Princess Margaret Hospital, Toronto, ON, Canada; Proteolix, South San Francisco, CA; Proteolix, Inc., South San Francisco, CA; Hackensack University Medical Center, Hackensack, NJ; University of North Carolina, Chapel Hill, NC
| | - A. Goy
- Mayo Clinic Arizona, Scottsdale, AZ; Memorial Sloan-Kettering Cancer Center, New York, NY; H. Lee Moffitt Cancer Center, Tampa, FL; Princess Margaret Hospital, Toronto, ON, Canada; Proteolix, South San Francisco, CA; Proteolix, Inc., South San Francisco, CA; Hackensack University Medical Center, Hackensack, NJ; University of North Carolina, Chapel Hill, NC
| | - R. Z. Orlowski
- Mayo Clinic Arizona, Scottsdale, AZ; Memorial Sloan-Kettering Cancer Center, New York, NY; H. Lee Moffitt Cancer Center, Tampa, FL; Princess Margaret Hospital, Toronto, ON, Canada; Proteolix, South San Francisco, CA; Proteolix, Inc., South San Francisco, CA; Hackensack University Medical Center, Hackensack, NJ; University of North Carolina, Chapel Hill, NC
| |
Collapse
|
36
|
Goy A, Feldman T, Dessanti M, Hainsworth J, Weaver C, Ungerleider R, Wolff A, Escandon R. A phase I-II study to assess the safety, pharmacokinetics, and potential efficacy of intravenous SB-743921 on days 1 and 15 of a 28-day cycle in patients with non-Hodgkin lymphoma. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.18516] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
18516 Background: Kinesin spindle protein (KSP) is required for mitotic spindle bipolarity and cell cycle progression. SB-743921 (SB- 921), a selective KSP inhibitor, blocks mitotic spindle assembly, causing cell cycle arrest in mitosis and subsequent cell death. Neutropenia was the dose-limiting toxicity (DLT) in the first-in-humans study of SB-921 given Q21 days. Methods: Cohort 1 of the Phase I portion of a study determining the safety, pharmacokinetics and MTD of SB-921 without prophylactic GCSF in patients (pts) with Non-Hodgkin’s Lymphoma (NHL) or Hodgkin’s Disease is reported. Pts with relapsed or refractory disease were eligible if they had received at least one prior chemotherapy regimen, had failed high-dose therapy with autologous stem cell transplant (ASCT), or were not candidates for ASCT. SB-921 is given to dose-escalating cohorts of 3 pts as a 1 hr IV infusion, Q14 days. Dosing began at 2 mg/m2 and escalated in 1 mg/m2 increments after 3 pts tolerated 1 cycle. Pts without dose-limiting toxicity (DLT) not completing Cycle 1 are replaced. Cohort expansion to 6 pts occurs if 1/3 pts experiences DLT, defined as any drug-related toxicity = grade 3 or drug-related grade 4 hematologic toxicity. Results: Cohort 1 (2 mg/m2) enrolled 6 NHL pts (5 indolent, 1 aggressive). 4 were female; median age = 59 (52–73); 5 Caucasian, 1 African-American; median no. of cycles = 2 (1–6). 5/6 pts were evaluable; 1 dropped out before dosing. The most common Grade 1–2 AEs, in decreasing order, were fatigue, dysgeusia, paresthesia, leukopenia, and diarrhea. Grade 3 AEs of note were 1 each of hemolytic anemia, leukopenia, thrombocytopenia and dyspnea; 1 Grade 4 anemia was reported. Conclusions: SB-921 was well tolerated without prophylactic GCSF in Cohort 1 of the Phase I portion of this study, which continues to dose-escalate. If neutropenia is the DLT, dose escalation will continue with prophylactic GCSF. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- A. Goy
- Hackensack University Medical Center, Hackensack, NJ; Sarah Cannon Cancer Center, Nashville, TN; Theradex, Inc, Princeton, NJ; Cytokinetics Inc, South San Francisco, CA
| | - T. Feldman
- Hackensack University Medical Center, Hackensack, NJ; Sarah Cannon Cancer Center, Nashville, TN; Theradex, Inc, Princeton, NJ; Cytokinetics Inc, South San Francisco, CA
| | - M. Dessanti
- Hackensack University Medical Center, Hackensack, NJ; Sarah Cannon Cancer Center, Nashville, TN; Theradex, Inc, Princeton, NJ; Cytokinetics Inc, South San Francisco, CA
| | - J. Hainsworth
- Hackensack University Medical Center, Hackensack, NJ; Sarah Cannon Cancer Center, Nashville, TN; Theradex, Inc, Princeton, NJ; Cytokinetics Inc, South San Francisco, CA
| | - C. Weaver
- Hackensack University Medical Center, Hackensack, NJ; Sarah Cannon Cancer Center, Nashville, TN; Theradex, Inc, Princeton, NJ; Cytokinetics Inc, South San Francisco, CA
| | - R. Ungerleider
- Hackensack University Medical Center, Hackensack, NJ; Sarah Cannon Cancer Center, Nashville, TN; Theradex, Inc, Princeton, NJ; Cytokinetics Inc, South San Francisco, CA
| | - A. Wolff
- Hackensack University Medical Center, Hackensack, NJ; Sarah Cannon Cancer Center, Nashville, TN; Theradex, Inc, Princeton, NJ; Cytokinetics Inc, South San Francisco, CA
| | - R. Escandon
- Hackensack University Medical Center, Hackensack, NJ; Sarah Cannon Cancer Center, Nashville, TN; Theradex, Inc, Princeton, NJ; Cytokinetics Inc, South San Francisco, CA
| |
Collapse
|
37
|
Goy A, Bernstein SH, Kahl BS, Djulbegovic B, Robertson MJ, Boral A, Shi H, Fisher RI. Bortezomib in relapsed or refractory mantle cell lymphoma (MCL): Results of the PINNACLE study. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.7512] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
7512 Background: Bortezomib (VELCADE, Vc), a novel proteasome inhibitor, is approved in relapsed multiple myeloma and has shown activity in MCL in phase 2 NHL studies. Methods: Patients (pts) with relapsed or refractory MCL with a maximum of 2 prior therapies received Vc 1.3mg/m2 i.v. on d 1, 4, 8, and 11 of a 21-d cycle for up to 1y. Full accrual (155 pts) was completed in this multicenter, phase 2 study. Primary endpoint was TTP, secondary endpoints included RR and duration of response (DOR). Response (International Workshop Criteria) was assessed by the investigators and separately by the sponsor using central radiology review. Results: Data are available for 154 pts. Baseline characteristics included median age 65y, 81% male, 28% KPS <90%, 35% LDH > normal, 43% IPI ≥3, 74% stage IV MCL. 90% of pts had prior intensive therapy (e.g. Hyper CVAD, CHOP, EPOCH), 96% had prior rituximab, and 14% had prior stem cell transplant. Median duration of Vc treatment was 4 cycles. 138 pts were evaluable for response. By investigator assessment, RR was 35% (CR + CRu = 8%) and median DOR was 9.2 mo. Median TTP was 5.5 mo (all patients, n = 154). Using central radiology review RR was 31% (CR + CRu = 7%), median DOR was 4.6 mo and median TTP was 4.1 mo. With median follow-up of 10 mo, median survival has not been reached. The most common non-hematologic AEs were fatigue (14% ≥grade 3), GI events (≥grade 3 diarrhea, abdominal pain, and nausea/vomiting in 5%, 4%, and 3%, respectively), and peripheral neuropathies (7% ≥grade 3). Hematologic toxicities were minimal except for transient thrombocytopenia (10% ≥grade 3), as previously seen with Vc. Conclusions: This study confirms the activity of Vc in relapsed/refractory MCL in a multicenter international setting and supports its rapid development as a new treatment for relapsed MCL. Vc is also being studied in the first-line setting in combination with standard chemotherapy. [Table: see text]
Collapse
Affiliation(s)
- A. Goy
- Hackensack University Medical Center, Hackensack, NJ; University of Rochester School of Medicine and Dentistry, Rochester, NY; University of Wisconsin, Madison, WI; H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL; Indiana University School of Medicine, Indianapolis, IN; Millennium Pharmaceuticals, Inc, Cambridge, MA; University of Rochester, Rochester, NY
| | - S. H. Bernstein
- Hackensack University Medical Center, Hackensack, NJ; University of Rochester School of Medicine and Dentistry, Rochester, NY; University of Wisconsin, Madison, WI; H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL; Indiana University School of Medicine, Indianapolis, IN; Millennium Pharmaceuticals, Inc, Cambridge, MA; University of Rochester, Rochester, NY
| | - B. S. Kahl
- Hackensack University Medical Center, Hackensack, NJ; University of Rochester School of Medicine and Dentistry, Rochester, NY; University of Wisconsin, Madison, WI; H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL; Indiana University School of Medicine, Indianapolis, IN; Millennium Pharmaceuticals, Inc, Cambridge, MA; University of Rochester, Rochester, NY
| | - B. Djulbegovic
- Hackensack University Medical Center, Hackensack, NJ; University of Rochester School of Medicine and Dentistry, Rochester, NY; University of Wisconsin, Madison, WI; H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL; Indiana University School of Medicine, Indianapolis, IN; Millennium Pharmaceuticals, Inc, Cambridge, MA; University of Rochester, Rochester, NY
| | - M. J. Robertson
- Hackensack University Medical Center, Hackensack, NJ; University of Rochester School of Medicine and Dentistry, Rochester, NY; University of Wisconsin, Madison, WI; H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL; Indiana University School of Medicine, Indianapolis, IN; Millennium Pharmaceuticals, Inc, Cambridge, MA; University of Rochester, Rochester, NY
| | - A. Boral
- Hackensack University Medical Center, Hackensack, NJ; University of Rochester School of Medicine and Dentistry, Rochester, NY; University of Wisconsin, Madison, WI; H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL; Indiana University School of Medicine, Indianapolis, IN; Millennium Pharmaceuticals, Inc, Cambridge, MA; University of Rochester, Rochester, NY
| | - H. Shi
- Hackensack University Medical Center, Hackensack, NJ; University of Rochester School of Medicine and Dentistry, Rochester, NY; University of Wisconsin, Madison, WI; H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL; Indiana University School of Medicine, Indianapolis, IN; Millennium Pharmaceuticals, Inc, Cambridge, MA; University of Rochester, Rochester, NY
| | - R. I. Fisher
- Hackensack University Medical Center, Hackensack, NJ; University of Rochester School of Medicine and Dentistry, Rochester, NY; University of Wisconsin, Madison, WI; H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL; Indiana University School of Medicine, Indianapolis, IN; Millennium Pharmaceuticals, Inc, Cambridge, MA; University of Rochester, Rochester, NY
| |
Collapse
|
38
|
Goy A, Bernstein S, Kahl B, Epner E, Leonard JP, Stadtmauer E, Morgan D, Belt R, Baidas S, Fisher RI. Bortezomib in patients with relapsed or refractory mantle cell lymphoma (MCL): Preliminary results of the PINNACLE study. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.6563] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- A. Goy
- MD Anderson Cancer Ctr, Houston, TX; Univ of Rochester, Rochester, NY; Univ Hosp - Madison, Madison, WI; Oregon Health Sciences Univ, Portland, OR; New York Weill-Cornell Medcl Ctr, New York, NY; Univ of Pennsylvania Cancer Ctr, Philadelphia, PA; Vanderbilt Univ, Nashville, TN; Kansas City Cancer Ctr, Kansas City, MO; Georgetown Univ Medcl Ctr, Washington, DC
| | - S. Bernstein
- MD Anderson Cancer Ctr, Houston, TX; Univ of Rochester, Rochester, NY; Univ Hosp - Madison, Madison, WI; Oregon Health Sciences Univ, Portland, OR; New York Weill-Cornell Medcl Ctr, New York, NY; Univ of Pennsylvania Cancer Ctr, Philadelphia, PA; Vanderbilt Univ, Nashville, TN; Kansas City Cancer Ctr, Kansas City, MO; Georgetown Univ Medcl Ctr, Washington, DC
| | - B. Kahl
- MD Anderson Cancer Ctr, Houston, TX; Univ of Rochester, Rochester, NY; Univ Hosp - Madison, Madison, WI; Oregon Health Sciences Univ, Portland, OR; New York Weill-Cornell Medcl Ctr, New York, NY; Univ of Pennsylvania Cancer Ctr, Philadelphia, PA; Vanderbilt Univ, Nashville, TN; Kansas City Cancer Ctr, Kansas City, MO; Georgetown Univ Medcl Ctr, Washington, DC
| | - E. Epner
- MD Anderson Cancer Ctr, Houston, TX; Univ of Rochester, Rochester, NY; Univ Hosp - Madison, Madison, WI; Oregon Health Sciences Univ, Portland, OR; New York Weill-Cornell Medcl Ctr, New York, NY; Univ of Pennsylvania Cancer Ctr, Philadelphia, PA; Vanderbilt Univ, Nashville, TN; Kansas City Cancer Ctr, Kansas City, MO; Georgetown Univ Medcl Ctr, Washington, DC
| | - J. P. Leonard
- MD Anderson Cancer Ctr, Houston, TX; Univ of Rochester, Rochester, NY; Univ Hosp - Madison, Madison, WI; Oregon Health Sciences Univ, Portland, OR; New York Weill-Cornell Medcl Ctr, New York, NY; Univ of Pennsylvania Cancer Ctr, Philadelphia, PA; Vanderbilt Univ, Nashville, TN; Kansas City Cancer Ctr, Kansas City, MO; Georgetown Univ Medcl Ctr, Washington, DC
| | - E. Stadtmauer
- MD Anderson Cancer Ctr, Houston, TX; Univ of Rochester, Rochester, NY; Univ Hosp - Madison, Madison, WI; Oregon Health Sciences Univ, Portland, OR; New York Weill-Cornell Medcl Ctr, New York, NY; Univ of Pennsylvania Cancer Ctr, Philadelphia, PA; Vanderbilt Univ, Nashville, TN; Kansas City Cancer Ctr, Kansas City, MO; Georgetown Univ Medcl Ctr, Washington, DC
| | - D. Morgan
- MD Anderson Cancer Ctr, Houston, TX; Univ of Rochester, Rochester, NY; Univ Hosp - Madison, Madison, WI; Oregon Health Sciences Univ, Portland, OR; New York Weill-Cornell Medcl Ctr, New York, NY; Univ of Pennsylvania Cancer Ctr, Philadelphia, PA; Vanderbilt Univ, Nashville, TN; Kansas City Cancer Ctr, Kansas City, MO; Georgetown Univ Medcl Ctr, Washington, DC
| | - R. Belt
- MD Anderson Cancer Ctr, Houston, TX; Univ of Rochester, Rochester, NY; Univ Hosp - Madison, Madison, WI; Oregon Health Sciences Univ, Portland, OR; New York Weill-Cornell Medcl Ctr, New York, NY; Univ of Pennsylvania Cancer Ctr, Philadelphia, PA; Vanderbilt Univ, Nashville, TN; Kansas City Cancer Ctr, Kansas City, MO; Georgetown Univ Medcl Ctr, Washington, DC
| | - S. Baidas
- MD Anderson Cancer Ctr, Houston, TX; Univ of Rochester, Rochester, NY; Univ Hosp - Madison, Madison, WI; Oregon Health Sciences Univ, Portland, OR; New York Weill-Cornell Medcl Ctr, New York, NY; Univ of Pennsylvania Cancer Ctr, Philadelphia, PA; Vanderbilt Univ, Nashville, TN; Kansas City Cancer Ctr, Kansas City, MO; Georgetown Univ Medcl Ctr, Washington, DC
| | - R. I. Fisher
- MD Anderson Cancer Ctr, Houston, TX; Univ of Rochester, Rochester, NY; Univ Hosp - Madison, Madison, WI; Oregon Health Sciences Univ, Portland, OR; New York Weill-Cornell Medcl Ctr, New York, NY; Univ of Pennsylvania Cancer Ctr, Philadelphia, PA; Vanderbilt Univ, Nashville, TN; Kansas City Cancer Ctr, Kansas City, MO; Georgetown Univ Medcl Ctr, Washington, DC
| |
Collapse
|
39
|
Duvic M, Talpur R, Zhang C, Goy A, Richon V, Frankel SR. Phase II trial of oral suberoylanilide hydroxamic acid (SAHA) for cutaneous T-cell lymphoma (CTCL) unresponsive to conventional therapy. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.6571] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- M. Duvic
- M.D. Anderson Cancer Ctr, Houston, TX; Merck Research Labs, Boston, MA; Merck Research Labs, Blue Bell, PA
| | - R. Talpur
- M.D. Anderson Cancer Ctr, Houston, TX; Merck Research Labs, Boston, MA; Merck Research Labs, Blue Bell, PA
| | - C. Zhang
- M.D. Anderson Cancer Ctr, Houston, TX; Merck Research Labs, Boston, MA; Merck Research Labs, Blue Bell, PA
| | - A. Goy
- M.D. Anderson Cancer Ctr, Houston, TX; Merck Research Labs, Boston, MA; Merck Research Labs, Blue Bell, PA
| | - V. Richon
- M.D. Anderson Cancer Ctr, Houston, TX; Merck Research Labs, Boston, MA; Merck Research Labs, Blue Bell, PA
| | - S. R. Frankel
- M.D. Anderson Cancer Ctr, Houston, TX; Merck Research Labs, Boston, MA; Merck Research Labs, Blue Bell, PA
| |
Collapse
|
40
|
Anderlini P, Saliba R, Acholonu S, Okoroji GJ, Donato M, Giralt S, Andersson B, Ueno NT, Khouri I, De Lima M, Hosing C, Cohen A, Ippoliti C, Romaguera J, Rodriguez MA, Pro B, Fayad L, Goy A, Younes A, Champlin RE. Reduced-intensity allogeneic stem cell transplantation in relapsed and refractory Hodgkin's disease: low transplant-related mortality and impact of intensity of conditioning regimen. Bone Marrow Transplant 2005; 35:943-51. [PMID: 15806128 DOI: 10.1038/sj.bmt.1704942] [Citation(s) in RCA: 106] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
A total of 40 patients with relapsed/refractory Hodgkin's disease (HD) underwent reduced-intensity conditioning (RIC) allogeneic stem cell transplantation (allo-SCT) from an HLA-identical sibling (n=20) or a matched unrelated donor (n=20). The median age was 31 years (range 18-58). Disease status at allo-SCT was refractory relapse (n=14) or sensitive relapse (n=26). The conditioning regimens were fludarabine-cyclophosphamide+/-antithymocyte globulin (n=14), a less intensive regimen, and fludarabine-melphalan (FM) (n=26), a more intensive one. The two groups had similar prognostic factors. The median time to neutrophil recovery (ie absolute neutrophil count >/=500/microl) was 12 days (range 10-24). The median time to platelet recovery (ie platelet count >/=20 000/microl) was 17 days (range 7-132). Day 100 and cumulative (18-month) transplant-related mortalities (TRMs) were 5 and 22%. Twenty-four patients (60%) are alive (14 in complete remission or complete remission, unconfirmed/uncertain) with a median follow-up of 13 months (4-78). In all, 16 patients expired (TRM n=8, disease progression n=8). FM patients had better overall survival (73 vs 39% at 18 months; P=0.03), and a trend towards better progression-free survival (37 vs 21% at 18 months; P=0.2). RIC allo-SCT is feasible in relapsed/refractory HD patients with a low TRM. The intensity of the preparative regimen affects survival.
Collapse
Affiliation(s)
- P Anderlini
- Department of Blood and Marrow Transplantation, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
41
|
Rodriguez MA, Dang NH, Fayad L, Goy A, Hagemeister FB, McLaughlin P, Pro B, Romaguera JE, Younes A, Cabanillas F. Sphingosomal vincristine in CHOP is a promising new treatment for elderly, as well as poor prognosis patients with aggressive non-Hodgkin's lymphoma (NHL): Follow-up results of a phase II study. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.8080] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
| | - N. H. Dang
- UT MD Anderson Cancer Center, Houston, TX
| | - L. Fayad
- UT MD Anderson Cancer Center, Houston, TX
| | - A. Goy
- UT MD Anderson Cancer Center, Houston, TX
| | | | | | - B. Pro
- UT MD Anderson Cancer Center, Houston, TX
| | | | - A. Younes
- UT MD Anderson Cancer Center, Houston, TX
| | | |
Collapse
|
42
|
Jiang Y, Goy A, Fritsche HA, Von Mensdorff-Pouilly S, Lichtiger B, Hess M, Simons D, Remache Y, Cabanillas F, Gilles F. Prognostic value of soluble MUC1 and anti-MUC1 antibody levels in patients with diffuse large B-cell lymphoma. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.6586] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- Y. Jiang
- M.D. Anderson Cancer Center, Houston, TX; Vrije Universiteit Medical Center, Amsterdam, Netherlands
| | - A. Goy
- M.D. Anderson Cancer Center, Houston, TX; Vrije Universiteit Medical Center, Amsterdam, Netherlands
| | - H. A. Fritsche
- M.D. Anderson Cancer Center, Houston, TX; Vrije Universiteit Medical Center, Amsterdam, Netherlands
| | - S. Von Mensdorff-Pouilly
- M.D. Anderson Cancer Center, Houston, TX; Vrije Universiteit Medical Center, Amsterdam, Netherlands
| | - B. Lichtiger
- M.D. Anderson Cancer Center, Houston, TX; Vrije Universiteit Medical Center, Amsterdam, Netherlands
| | - M. Hess
- M.D. Anderson Cancer Center, Houston, TX; Vrije Universiteit Medical Center, Amsterdam, Netherlands
| | - D. Simons
- M.D. Anderson Cancer Center, Houston, TX; Vrije Universiteit Medical Center, Amsterdam, Netherlands
| | - Y. Remache
- M.D. Anderson Cancer Center, Houston, TX; Vrije Universiteit Medical Center, Amsterdam, Netherlands
| | - F. Cabanillas
- M.D. Anderson Cancer Center, Houston, TX; Vrije Universiteit Medical Center, Amsterdam, Netherlands
| | - F. Gilles
- M.D. Anderson Cancer Center, Houston, TX; Vrije Universiteit Medical Center, Amsterdam, Netherlands
| |
Collapse
|
43
|
Goy A, Younes A, McLaughlin P, Pro B, Romaguera J, Hagemeister F, Fayad L, Trehu EG, Schenkein D, Rodriguez MA. Update on a phase (ph) 2 study of bortezomib in patients (pts) with relapsed or refractory indolent or aggressive non-Hodgkin's lymphomas (NHL). J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.6581] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- A. Goy
- The University of Texas M. D. Anderson Cancer Center, Houston, TX; Millennium Pharmaceuticals, Inc., Cambridge, MA
| | - A. Younes
- The University of Texas M. D. Anderson Cancer Center, Houston, TX; Millennium Pharmaceuticals, Inc., Cambridge, MA
| | - P. McLaughlin
- The University of Texas M. D. Anderson Cancer Center, Houston, TX; Millennium Pharmaceuticals, Inc., Cambridge, MA
| | - B. Pro
- The University of Texas M. D. Anderson Cancer Center, Houston, TX; Millennium Pharmaceuticals, Inc., Cambridge, MA
| | - J. Romaguera
- The University of Texas M. D. Anderson Cancer Center, Houston, TX; Millennium Pharmaceuticals, Inc., Cambridge, MA
| | - F. Hagemeister
- The University of Texas M. D. Anderson Cancer Center, Houston, TX; Millennium Pharmaceuticals, Inc., Cambridge, MA
| | - L. Fayad
- The University of Texas M. D. Anderson Cancer Center, Houston, TX; Millennium Pharmaceuticals, Inc., Cambridge, MA
| | - E. G. Trehu
- The University of Texas M. D. Anderson Cancer Center, Houston, TX; Millennium Pharmaceuticals, Inc., Cambridge, MA
| | - D. Schenkein
- The University of Texas M. D. Anderson Cancer Center, Houston, TX; Millennium Pharmaceuticals, Inc., Cambridge, MA
| | - M. A. Rodriguez
- The University of Texas M. D. Anderson Cancer Center, Houston, TX; Millennium Pharmaceuticals, Inc., Cambridge, MA
| |
Collapse
|
44
|
Sarris AH, Phan A, Goy A, Romaguera J, Hagemeister FB, Rodriguez MA, McLaughlin P, Pro B, Medeiros LJ, Samuels B, Mesina O, Bleyer AW, Cabanillas F. Irinotecan in relapsed or refractory non-Hodgkin's lymphomas. Indications of activity in a phase II trial. Oncology (Williston Park) 2002; 16:27-31. [PMID: 12199630] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Subscribe] [Scholar Register] [Indexed: 02/26/2023]
Abstract
Because irinotecan (CPT-11, Camptosar) is a topoisomerase I inhibitor with a broad spectrum of antitumor clinical activity, we investigated its activity in relapsed or refractory non-Hodgkin's lymphomas (NHLs). Irinotecan at 300 mg/m2 i.v. was administered every 21 days with intensive loperamide management of diarrhea. Responders received up to six treatment cycles. Of 44 registered patients, 32 are evaluable for response. Seventeen patients had received one previous regimen, and 15 patients had received two. Disease was refractory to the regimen preceding irinotecan in 12 patients. At baseline, serum lactate dehydrogenase levels were high in 47% (14/30), and beta-2-microglobulin levels were higher than 3.0 mg/L in 29% (8/28) of patients. Responses were seen in 12 of 32 (38%) patients (95% confidence interval [CI] = 21%-56%). Response rates were 43% for seven indolent (95% CI = 10%-82%), 0% for three mantle cell (95% CI = 0%-71%), 44% for 18 relapsed aggressive (95% CI = 22%-69%), and 20% for five refractory aggressive NHLs (95% CI = 1%-72%). Grade 3/4 toxicities included myelosuppression, neutropenic fever, and diarrhea. Irinotecan appears active and relatively well tolerated in patients with relapsed aggressive or indolent NHL. Accrual to this study is continuing for better determination of response rates in all histologic subtypes of NHL.
Collapse
Affiliation(s)
- A H Sarris
- Department of Lymphoma and Myeloma, The University of Texas M. D. Anderson Cancer Center, Houston, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
45
|
Turlakow A, Yeung HW, Pui J, Macapinlac H, Liebovitz E, Rusch V, Goy A, Larson SM. Fludeoxyglucose positron emission tomography in the diagnosis of giant cell arteritis. Arch Intern Med 2001; 161:1003-7. [PMID: 11295964 DOI: 10.1001/archinte.161.7.1003] [Citation(s) in RCA: 71] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/14/2022]
Abstract
We describe a case in which fludeoxyglucose F 18 positron emission tomography (PET) led directly to the diagnosis of giant cell arteritis in an elderly woman with a fever of unknown origin. The patient presented with a 3-month history of fatigue, fever, headache, visual disturbance, jaw claudication, and anemia. A computed tomographic scan showed an anterior mediastinal mass that was suspected of being malignant. A fludeoxyglucose F 18 PET scan performed for preoperative evaluation identified striking uptake of fludeoxyglucose F 18 in the walls of the entire aorta, left main coronary artery, and subclavian, carotid, and common iliac arteries bilaterally, suggestive of an arteritis, a diagnosis subsequently confirmed by the findings of an arterial biopsy. Her erythrocyte sedimentation rate was 129 mm/h. There was normalizaton of the PET scan 2 weeks following treatment with prednisolone. This case suggests that fludeoxyglucose F 18 PET contributes to the noninvasive diagnosis of giant cell arteritis, as well as to the evaluation of the extent of disease, response to therapy, and disease recurrence.
Collapse
Affiliation(s)
- A Turlakow
- Nuclear Medicine Service, Memorial Sloan-Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA.
| | | | | | | | | | | | | | | |
Collapse
|
46
|
Moskowitz CH, Nimer SD, Zelenetz AD, Trippett T, Hedrick EE, Filippa DA, Louie D, Gonzales M, Walits J, Coady-Lyons N, Qin J, Frank R, Bertino JR, Goy A, Noy A, O'Brien JP, Straus D, Portlock CS, Yahalom J. A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model. Blood 2001; 97:616-23. [PMID: 11157476 DOI: 10.1182/blood.v97.3.616] [Citation(s) in RCA: 305] [Impact Index Per Article: 13.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
Salvage of patients with relapsed and refractory Hodgkin disease (HD) with high-dose chemoradiotherapy (HDT) and autologous stem cell transplantation (ASCT) results in event-free survival (EFS) rates from 30% to 50%. Unfortunately, the reduction in toxicity associated with modern supportive care has improved EFS by only 5% to 10% and has not reduced the relapse rate. Results of a comprehensive 2-step protocol encompassing dose-dense and dose-intense second-line chemotherapy, followed by HDT and ASCT, are reported. Sixty-five consecutive patients, 22 with primary refractory HD and 43 with relapsed HD, were treated with 2 biweekly cycles of ifosfamide, carboplatin, and etoposide (ICE). Peripheral blood progenitor cells from responding patients were collected, and the patients were given accelerated fractionation involved field radiotherapy (IFRT) followed by cyclophosphamide-etoposide and either intensive accelerated fractionation total lymphoid irradiation or carmustine and ASCT. The EFS rate at a median follow-up of 43 months, as analyzed by intent to treat, was 58%. The response rate to ICE was 88%, and the EFS rate for patients who underwent transplantation was 68%. Cox regression analysis identified 3 factors before the initiation of ICE that predicted for outcome: B symptoms, extranodal disease, and complete remission duration of less than 1 year. EFS rates were 83% for patients with 0 to 1 adverse factors, 27% for patients with 2 factors, and 10% for patients with 3 factors (P <.001). These results compare favorably with other series and document the feasibility and efficacy of giving uniform dose-dense and dose-intense cytoreductive chemotherapy and integrating accelerated fractionation radiotherapy into an ASCT treatment program. This prognostic model provides a basis for risk-adapted HDT.
Collapse
Affiliation(s)
- C H Moskowitz
- Lymphoma and Hematology Disease Management Teams, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
47
|
Goy A, Gilles F, Remache Y, Filippa D, Portlock CS, Jhanwar SC, Zelenetz AD. Establishment of a human cell line (SKI-DLCL-1) with a t(1;14)(q21;q32) translocation from the ascites of a patient with diffuse large cell lymphoma. Leuk Lymphoma 2001; 40:419-23. [PMID: 11426565 DOI: 10.3109/10428190109057942] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
Cytogenetic abnormalities at chromosome 1q21 are among the most common second genetic events observed in Non-Hodgkin's Lymphomas and have prognostic significance. Recently, BCL9 has been cloned from a pre-B-cell lymphoblastic leukemia cell line, which carried a t(1:14)(q21;q32). However, among a panel of 39 B-cell malignancies with 1q21 translocation, only two cases showed rearrangement for the BCL9 gene. We report the establishment of a new lymphoma cell line from a patient with relapsed diffuse large cell lymphoma. This cell line SKI-DLCL-1 showed cell surface antigens identical to the original tumor and demonstrated the profile of a mature B-cell phenotype: CD19 and CD20 positive, CD5 and C10 negative. It carried a t(1;14)(q21;q32) translocation identical to the original tumor. Although the clinical presentation was an isolated effusion lymphoma, studies for HIV-1, HHV8 and EBV were all negative. Southern blot analysis demonstrated that BCL9 was not rearranged in the SKI-DLCL-1 cell line. In addition, the BCL9 gene was not over-expressed in SKI-DLCL-1 cell line. The identification of a new locus at 1q21 will help clarify the pathogenesis of B-cell malignancies with a translocation involving this locus.
Collapse
MESH Headings
- Aged
- Ascites/genetics
- Ascites/pathology
- Chromosomes, Human, Pair 1
- Chromosomes, Human, Pair 14
- Cytogenetic Analysis
- Humans
- Lymphoma, B-Cell/genetics
- Lymphoma, B-Cell/pathology
- Lymphoma, Large B-Cell, Diffuse/genetics
- Lymphoma, Large B-Cell, Diffuse/pathology
- Male
- Translocation, Genetic/genetics
- Tumor Cells, Cultured/cytology
- Tumor Cells, Cultured/metabolism
Collapse
Affiliation(s)
- A Goy
- Department of Medicine, Memorial Hospital, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA
| | | | | | | | | | | | | |
Collapse
|
48
|
Gilles F, Goy A, Remache Y, Manova K, Zelenetz AD. Cloning and characterization of a Golgin-related gene from the large-scale polymorphism linked to the PML gene. Genomics 2000; 70:364-74. [PMID: 11161787 DOI: 10.1006/geno.2000.6388] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
Megabase-scale mapping of the PML gene locus revealed the presence of a large-scale insertion-deletion polymorphism located 25 kb downstream of the PML gene. The polymorphism is organized as a head-to-tail tandem 25-kb repeat containing one to five units. Characterization of the first repeat unit downstream of PML revealed the presence of a gene with strong homology to a family of Golgin-related proteins. The gene, designated GLP (for Golgin linked to PML), is strongly expressed as a 6-kb transcript in normal human testis. In situ hybridization of normal human testis demonstrated that the expression of GLP was restricted to late meiotic germ cells. There was weak expression in late pachytene spermatocytes and strong expression in spermatids. GLP is 50% homologous to other Golgin-related proteins including the vesicle docking protein GM130. Southern blot hybridization of genomic DNA with a GLP probe demonstrated numerous homologous bands outside the PML locus. Three of these loci have been mapped by fluorescence in situ hybridization to chromosome loci 9q34.1, 15q11-q13, and 15q22-q24. Hybridization of a GLP cDNA probe to a zoo blot demonstrated multiple signals in nonhuman primates but not in other species and suggested the duplication of an ancestral locus around 20 million years ago.
Collapse
Affiliation(s)
- F Gilles
- Laboratory of Molecular Hemato-Oncology, Memorial Hospital, New York, New York 10021, USA
| | | | | | | | | |
Collapse
|
49
|
Goy A, Gilles F, Remache Y, Zelenetz AD. Physical linkage of the lysyl oxidase-like (LOXL1) gene to the PML gene on human chromosome 15q22. Cytogenet Cell Genet 2000; 88:22-4. [PMID: 10773658 DOI: 10.1159/000015477] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
A contig was constructed centered on the PML (promyelocytic leukemia) gene. Using an exon-trapping approach to identify potential genes from a pool of cosmids located 5' of the PML gene, four exons were identified that showed 100% sequence homology with the previously cloned lysyl oxidase-like (LOXL1) gene. An exon probe identified a single transcript of 2.4 kb on a multitissue Northern blot with a pattern identical to the one reported for the LOXL1 gene. Pulsed-field gel electrophoresis showed comigrating bands for both the PML cDNA and LOXL1 probes, demonstrating a physical linkage between these two genes. These data provide physical mapping information to complement the previous cytogenetic localization of LOXL1.
Collapse
MESH Headings
- Blotting, Southern
- Chromosomes, Human, Pair 15/genetics
- Cloning, Molecular
- Contig Mapping
- Electrophoresis, Gel, Pulsed-Field
- Exons/genetics
- Genetic Linkage/genetics
- Humans
- Neoplasm Proteins/genetics
- Nuclear Proteins
- Polymorphism, Genetic/genetics
- Promyelocytic Leukemia Protein
- Protein-Lysine 6-Oxidase/genetics
- RNA, Messenger/analysis
- RNA, Messenger/genetics
- Sequence Homology, Nucleic Acid
- Transcription Factors/genetics
- Tumor Suppressor Proteins
Collapse
Affiliation(s)
- A Goy
- Molecular Biology Program of Sloan-Kettering Institute and Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA
| | | | | | | |
Collapse
|
50
|
Gilles F, Goy A, Remache Y, Shue P, Zelenetz AD. MUC1 dysregulation as the consequence of a t(1;14)(q21;q32) translocation in an extranodal lymphoma. Blood 2000; 95:2930-6. [PMID: 10779441] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/16/2023] Open
Abstract
Cytogenetic abnormalities at chromosome 1q21 are among the most common lesions in diffuse large-cell lymphoma and have been associated with a poor prognosis. A novel cell line, SKI-DLCL-1, was established from ascitic fluid that carries a t(1;14)(q21;q32) chromosomal translocation. Using pulsed-field gel electrophoresis, the breakpoint on the IgH locus mapped to a gamma locus between Calpha(1) and Calpha(2). A cosmid library was prepared from SKI-DLCL-1, and Cgamma-positive clones spanning the breakpoint were identified by screening with fluorescence in situ hybridization. The breakpoint occurs 860 bp downstream of the 3' UTR of the MUC1 gene. The break appears to be a staggered double-strand break consistent with an error in immunoglobulin class switching. The MUC1 gene is highly transcribed and translated, and the protein is highly glycosylated. It is postulated that MUC1 expression is brought under the control of the 3'Ealpha enhancer. MUC1 lies in a region of chromosome 1 characterized by an unusually high density of genes, with 7 known genes in a region of approximately 85 kb. To determine whether there was a pleiotropic effect of the expression of genes in the region as a consequence of the translocation, the expression of 6 additional genes was assessed. None of the other genes in this region (CLK2, propin, COTE1, GBA, metaxin, and thrombospondin 3) are overexpressed in SKI-DLCL-1. Thus, the translocation t(1;14)(q21;q32) seen in both the primary tumor and the derived cell line results in the marked overexpression of MUC1 without affecting the expression of other genes in the region. (Blood. 2000;95:2930-2936)
Collapse
Affiliation(s)
- F Gilles
- Laboratory of Molecular Hemato-Oncology, the Lymphoma Service, and the Department of Medicine, Memorial Hospital, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA
| | | | | | | | | |
Collapse
|